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resumo 
 
 
T-complex testis expressed protein 1 domain containing 4 (TCTEX1D4) é uma 
cadeia leve de dineina que foi identificada como sendo uma proteína que 
interage com a PPP1. As funções específicas da TCTEX1D4 ainda 
permanecem desconhecidas mas a identificação dos seus interactores pode 
elucidar sobre as suas funções em sistemas biológicos. No interactoma da 
TCTEX1D4 merece particular destaque a presença de diversas proteínas 
associadas à via de sinalização do TGFβ e cuja desregulação se encontra 
associada ao cancro da próstata. Desta forma, foi objectivo deste trabalho 
avaliar a existência de TCTEX1D4 e do complexo TCTEX1D4-PPP1 em 
células de cancro da próstata, procurar desvendar o papel da TCTEX1D4 na 
via de sinalização do TGFβ e identificar eventuais alterações associadas à 
malginidade no cancro da próstata. 
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abstract 
 
T-complex testis expressed protein 1 domain containing 4 (TCTEX1D4) is a 
dynein light chain that has been identified as interacting with PPP1. Whilst 
specific functions of TCTEX1D4 remain unclear, the identification of its 
interactors may help elucidating its biological function. Concerning to 
TCTEX1D4 interactome, the presence of several proteins of the TGFβ 
signaling pathway which deregulation is associated with prostate cancer is of 
particular interest. Thereof, it was purpose of this work to assess of existence 
of TCTEX1D4 and the TCTEX1D4-PPP1 complex in prostate cancer cells, 
clarify its role within the TGFβ signaling pathway and identify possible 
alterations during prostate cancer carcinogenesis. 
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I. 1. Prostate gland  
Prostate is the largest male accessory gland, located in the subperitoneal 
compartment between the pelvic diaphragm and the peritoneal cavity [5, 6]. The 
human prostate is composed of one non-glandular or stromal and three glandular 
compartments, tightly fused within a pseudocapsule [5, 7]. The three glandular 
elements are: central zone (CZ), transition zone (TZ) and peripheral zone (PZ), 
with the non-glandular zone being the anterior fibromuscular stroma (AFS) [5, 6]. 
The localization of the human prostate in the male reproductive tract and its 
division is depicted in Figure 1. 
 
Figure 1 - A) Localization of the prostate gland in the male reproductive tract. B) Zonal 
division of the prostate. R – Rectum; SV - Seminal Vesicles; A – Anus; PS – Pubic 
Symphysis; AFS - Anterior Fibromuscular Stroma; TZ - Transition Zone; CZ - Central 
Zone; PZ - Peripheral Zone. Adapted from[8, 9]. 
These zones have different embryologic origins and can be distinguished by their 
histology, anatomic landmarks, biological functions and susceptibility to pathologic 
disorders, as summarized in Table 1 [5, 10].  
Table 1 - Prostate gland is divided into three zones with different embryonic origins, 
histological and pathological findings. PCa – Prostate cancer; BPH – Benign Prostatic 
Hyperplasia.  
Feature/Zone Central Zone Transition Zone Peripheral Zone 
Volume 25% 5% 70% 
Embryonic Origin Wolffian Duct Urogenital Sinus 
Epithelium 
Complex, large 
polygonal glands 
Simple, small rounded glands 
Stroma Compact Fibromuscular Loose 
Origin of PCa 5% 25% 70% 
Origin of BPH - 100% - 
 
 
A B 
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The histologic architecture of the prostate is that of a branched duct gland. Two cell 
layers, a luminal secretory columnar cell layer and an underlying basal cell layer, 
line each duct [6, 10]. The predominant secretory cells are columnar and 
characterized by expression of androgen receptor (AR), cytokeratins 8 and 18, 
CD57, prostatic acid phosphatase (PAP), human kallikrein-2 and prostate-specific 
antigen (PSA). Basal cells are cuboid and express cytokeratins 5, 10, 11, 14, 15 
and 17, p63, CD44, and low levels of AR. Normal prostate also has neuroendocrine 
cells, which are androgen-independent and express chromogranin A and a variety 
of peptide hormones. The existence of epithelial stem cells in the prostate is well-
accepted and associated with the expression of cytokeratins 5 and 14 [2, 11]. 
Prostate cells are in close contact with a complex stroma consisting of smooth 
muscle, blood vessels, blood borne cells, nerves, fibroblasts and extensive 
extracellular matrix (ECM). All these components work as a functional unit, with 
interactions between stroma and epithelium playing a pivotal role in normal 
prostate growth, development and function [12]. 
Prostate has several functions. As an exocrine gland, it produces the prostatic fluid, 
which comprises 30% of the volume of the ejaculate. The pr1ostatic fluid contains 
several constituents, such as: 1) zinc, with anti-bacterial properties; 2) PAP and 
other enzymes and nutrients that nurture sperm; 3) coagulase and other 
substances related to coagulation that facilitate movement and fertilization;  4) 
through its pH it increases sperm viability by reducing the acidity of the urethra. 
Prostate also participates in the control of urinary output and ejaculation and 
contributes to the metabolism of testosterone, converting it to the most potent 
androgen Dihydrotestosterone (DHT) [6, 13]. 
It has been established that androgens, testosterone and DHT, are the most potent 
and relevant mitogens of the normal prostate. In fact, continuous stimulation by 
androgens is crucial for normal prostatic development and function. AR is usually 
located in the cytoplasm. Upon presence of the ligand, it is translocated to the 
nucleus, where it exerts its transcription factor activity, binding to Androgen-
Responsive Elements and promoting the transcription of target genes. Overall, it 
stimulates proliferation, differentiation and secretion. However, androgens actions 
are mainly indirect, through the stimulation of the production of diverse growth 
factors and its receptors. Among these, the more important ones are EGF, TGFα, 
KGF, IGF, NGF, PDGF and bFGF. In order to counteract the effects of these growth 
factors, both in stroma (bFGF) and epithelium (mainly TGFα and EGF), TGFβ has 
been identified as a key growth modulator in normal prostate, by inducing growth 
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inhibition and differentiation [6, 12, 14-16]. Commonly, these rely on intracellular 
pathways of signal transduction like JAK/STAT3, Ras/Raf/Mek/MAPK, Smads and 
PI3K/AKT/mTOR [17]. A more detailed description of the effects of androgens and 
other hormones and growth factors is presented in Table 2. 
Table 2 - Overview of the effects of hormones and growth factors in the prostate gland. 
Based on [6, 12, 14-16]. 
Hormone/Growth Factor Action 
Androgens 
Suppression of stromal growth; Increase in epithelial height and 
secretory activity; increases DNA synthesis, mRNA and Protein 
levels and enzymatic activity 
Estrogens 
Gonadotropin inhibition at hypothalamus or pituitary gland 
levels; Lowers epithelial height and secretion 
Gestagens Stimulates weight gain and secretion  
Prolactin 
Stimulates weight gain and secretion; Stimulates accumulation of 
androgens 
Insulin Stimulates weight gain and secretion; Prevents autophagy 
bFGF Mitogen, especially in stroma; Stimulates angiogenesis 
EGF and TGFα Mitogen, especially in epithelium  
PDGF, NGF, IGF, IL6 Mitogens; prevention of apoptosis 
TGFβ 
Prevents epithelial cell growth; Stimulates stromal cell growth 
and angiogenesis 
 
I. 2. Prostate cancer 
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are the two most 
common diseases in elderly men. Although they both occur in the same population, 
they are unrelated illnesses [5]. Worldwide, PCa is the 2nd most incident cancer in 
men, with 900 000 people diagnosed each year. In terms of cancer-related 
mortality, it ranks 6th worldwide (260 000 deaths each year). In Portugal, the 
situation is similar to other developed countries, with PCa being the most diagnosed 
cancer in men and 3rd cause of cancer-related death. Portuguese men have a 
lifetime risk of PCa diagnosis of 1/6 and 1 in every 35 portuguese men will die from 
PCa.  Notably, worldwide significant differences (up to 25-fold) in PCa epidemiology 
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are evident: PCa is far more common in Europe, Australia and North America, with 
lower incidence in Asia and Africa [12, 18-20]. This may be due to the existence of 
several environmental and inherited risk factors. The main risk factor for the 
general population is ageing. Other risk factors or proposed risk factors are listed in 
Table 3. 
Table 3 - Risk Factors associated with PCa. BRCA2 – Breast cancer 2, early onset; HPC1 
- hereditary prostate cancer 1; HPC2 - hereditary prostate cancer 2; HSV – Herpes 
Simplex Virus; HPV – Human Papil loma Virus; HCV – Hepatitis C Virus. Based on [21]. 
Type of Risk Factor Examples 
Familial Associated with BRCA2, HPC1, HPC2 mutations 
Ethnicity African American 
Pathological/Medical 
Vasectomy, Prostatitis, STDs (HSV, HPV, HCV,  
Gonorrhea, syphilis and chlamydia infections) 
Socioeconomic 
Income and education, occupation (farmers, 
plumbers, mechanics, etc.) 
Environmental/Behavioral 
Exposure to cadmium, smoking, diet, obesity, lack 
of exercise, sexual behavior 
 
I. 2. 1. Molecular basis of PCa 
The term cancer encompasses a heterogenic group of disorders that share a 
profound growth deregulation as a result of an accumulation of several somatic 
mutations that determine the progressive acquisition of malignity. Carcinomas of 
the prostate are often clinically silent, particularly during their early stages [22]. 
Locally advanced PCa may produce signs and symptoms including local discomfort 
and evidence of lower urinary tract obstruction. Occasionally, the first evidence of 
PCa is due to metastasis either in bone (the most common site of metastasis, 
causing bone pain or fractures) or in the liver (causing liver enlargement) [23]. The 
cellular origin of PCa has been attributed either to the dedifferentiation and 
mortality acquisition of differentiated luminal cells or to the malignant 
transformation of prostate stem cells that reside among the basal cells. It has also 
been observed that PCa can arise from basal cells, although the aggressive 
potential of luminal and basal cells populations differs [24]. Proliferative 
inflammatory atrophy (PIA), prostatic intraepithelial neoplasia (PIN) and atypical 
small acinar proliferation (ASAP) are regarded as the main PCa precursors, with 
several molecular mechanisms being proposed as triggers for each stage of 
progression and the alterations in each well-defined (Figure 2) [2]. PIA cells may 
undergo transformation leading to PCa directly or indirectly via the development of 
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High-Grade PIN [3]. ASAP are the precancerous lesions more related to cancer 
[25]. Despite the fact that most malignant tumors are monoclonal in origin, by the 
time they become clinically evident their constituent cells are extremely 
heterogeneous. At the molecular level, tumor progression most likely results from 
multiple mutations that accumulate independently in different cells, generating 
subclones with different characteristics [22]. Due to its marked heterogeneity and 
multifocal nature, the definition of a general mechanism of acquisition of malignity 
in PCa is rather difficult [26]. Even though some characteristic chromosomal 
changes and mutations have been defined (Figure 2), no single alteration can be 
defined as the cause of PCa. Besides alterations in genetic level, PCa also includes 
inflammation [27], oxidative stress and DNA damage [28], telomere shortening and 
telomerase activity [29] and epigenetic modifications [30], all of which contribute in 
a cooperative manner to the acquisition of malignity. Nevertheless, it appears that 
alterations in hormonal systems and growth factors signaling may represent a key 
aspect of PCa development and sustainability. Initially, the majority of the tumors 
are androgen-dependent.  However, they progress to an androgen-independent 
state [31]. Alterations in growth factors, its receptors and their signal transduction 
pathways are also described, namely in EGF, PDGF, TGFα and TGFβ [2, 26]. A 
closer insight into alterations of TGFβ signaling pathway in PCa will be presented 
below. 
I. 2. 2. Prostate Cancer – a need for new targets and biomarkers 
Most human prostatic carcinomas are initially responsive to androgen ablation 
therapy, surgical castration and radiotherapy. However, when prostatic carcinomas 
progress to androgen-independent tumors, radical prostatectomy is the only option 
for treatment [32]. Nonetheless, these therapeutic options present several side 
effects, including urinary incontinence and impotence [33]. After metastasis 
formation no curative treatment is currently available, being surgical or medical 
castration the standard palliative treatments, with androgen deprivation producing 
effects on 80% of patients [12]. Regarding PCa detection, digital rectal 
examination, PSA levels and transrectal ultrasonography are commonly used for 
screening although the utility of these (especially PSA) are under discussion. 
Nevertheless, biopsy is always necessary for a definitive diagnosis [34, 35]. Since 
PCa is usually a silent disease in the first stages, the establishment of a specific 
panel of biomarkers, in either tissue or body fluids, which might complement the 
routinely applied diagnosis techniques in order to achieve earlier and more accurate 
diagnosis is desirable [36].  
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I. 2. TGFβ signaling  
The transforming growth factor beta (TGFβ) superfamily comprises over than 42 
members, all of which are generated from a pre-pro-peptide precursor. Besides 
TGFβ1, 2 and 3, this superfamily includes the bone morphogenetic proteins (BMPs), 
the activins, the growth differentiation factors (GDFs) and the anti-muellerian 
hormone (AMH), among others [37]. Virtually all types of cells produce and are 
sensitive to TGFβ superfamily members. These play fundamental roles in several 
cellular processes which may vary according to the ligand, the tissue and the 
conditions [38].   
TGFβ is a cytokine with pleiotropic effects that is produced mainly by fibroblasts 
and epithelial cells [39]. In the epithelium, TGFβ inhibits cellular proliferation [40], 
whilst in the mesenchyme it promotes cellular proliferation [41, 42]. Other 
functions attributed to TGFβ are: synthesis of extracellular matrix [43], expression 
of integrins [44], modulation of immune response [45], angiogenesis [46] and 
wound healing [22]. BMPs display a broad range of effects distinct from those of 
TGFβ, even though sharing similar structure and signal transduction mechanisms. 
Among these, bone and cartilage formation and embryogenesis are the most 
relevant [47, 48]. Activins play crucial roles in the activation of FSH [49], 
erythropoiesis [50] and survival of neurons [51]. TGFβ family ligands dimerize, 
most commonly forming homodimers, and propagate the signal by interacting with 
membrane surface receptors presented in the target cell [52]. A total of 12 
transmembrane Ser/Thr kinase receptors have been identified which are usually 
divided into two types: 5 constitutively active type II receptors (TGFβRII) and 7 
non-constitutively active type I receptors (TGFβRI). Type III Receptors (or Co-
receptors), which lack catalytic activity, have also been identified, namely endoglin 
(CD105) and betaglycan (TGFβRIII), which facilitate the interaction between the 
ligand and TGFβRII [52] (Figure 3). Ligands display more affinity to the type II 
receptors and the binding of the TGFβ to the type II receptor enables it to 
phosphorylate the GS domain of the type I receptor, activating its catalytic activity 
[38, 53, 54]. The type I receptors are denominated activin receptors-like kinases 
(ALKs) and once activated exert their catalytic activity by phosphorylating the C-
terminal SxS domain in the main intracellular signal transducers of the pathway, 
the Smads [55]. Eight Smads have been identified in the human and mouse 
genomes: five regulatory Smads (R-Smads 1/2/3/5/8), one common Smad 
(Smad4, also known as Co-Smad) and two inhibitory Smads (I-Smads 6/7). The R-
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Smads, after being phosphorylated by the type I receptors, form trimers with the 
Co-Smad [55]. Generally, BMPs, AMH and some GDFs (like GDF10) bind to ALKs 
1/2/3/6 which propagate the signals via Smads 1/5/8, whereas TGFβ, Nodal, 
Activins and other GDFs (as GDF1) bind to ALKs 4/5/7 which propagate it through 
Smads 2/3 [38]. The fine dynamic equilibrium between these two opposing 
pathways often determines the ultimate outcome of the signal. After the formation 
of the complex, it is then translocated to the nucleus via microtubules and dyneins 
[35, 56].  
Once in the nucleus, the trimers act as transregulatory elements to activate or 
repress the expression of genes such as Sp1, Id1, Id2 and Myc. R-Smads/Co-Smad 
complex can also recruit transcription co-activators or co-repressors to modulate 
the amplitude of the activation/repression of the transcription [38]. Moreover, 
besides activating the canonical Smad-dependent signaling pathway, TGFβ can also 
activate other signaling pathways in a Smad-independent manner, such as MAPK, 
PI3K and small GTPases pathways [57, 58]. An overview of the TGFβ signaling 
pathways is depicted in Figure 3. 
I. 2.1 TGFβ signaling alterations in PCa 
During cell malignant transformation a number of alterations occur at molecular 
and cellular levels (genetic, epigenetic and somatic) and in the surrounding 
microenvironment contributing to an increased survivability and proliferative 
advantage [14, 59-61]. The traditional hallmarks of cancer were defined as: a) 
insensitivity to anti-growth signals; b) evasion of apoptosis; c) self-sufficiency in 
growth signals; d) sustained angiogenesis; e) limitless replicative potential; and f) 
tissue invasion and metastasis [62]. Moreover, two new emerging hallmarks, 
namely deregulation of the cellular energetics and avoidance of immune destruction 
have arisen. Additionally, two consequential characteristics of neoplasia facilitate 
the acquisition of the hallmarks previously defined, being these the genomic 
instability (and the consequent accumulation of mutations) and the tumor-
promoting inflammation [63]. 
TGFβ, as a potent pleiotropic cytokine, has a defined yet complex role in mediating 
each of these hallmarks [14]. In normal tissues TGFβ functions as a formidable 
barrier to the development of cancer hallmarks [64]. It inhibits cellular proliferation 
[65], migration and invasion [66], and promotes apoptosis [67], cell adhesion [66] 
and cellular differentiation [68]. 
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Figure 3 - TGFβ signaling pathway. Dimers of the TGFβ superfamily bind to type II 
TGFβR. TGFβ, Activin and Nodal bind to TGFβRII (or ActRII) which phosphorylates the 
ALKs 4/5/7 which propagates the signal via Smads2/3,  in a phosphorylation-dependent 
way. Co-receptors like endoglin or Betaglycan facil itate binding to TGFβRs  (Center, 
blue). On the opposite side, BMPs and AMH bind BMPRII, which phosphorylates ALKs 
2/3/6, which, in turn, propagate this signal through phosphorylation of Smad1/5/8 
(right, green). R-Smads form trimers which are translocated into the nucleus by 
dynenins and microtubules. In the nucleus they transregulate (TR) the expression of 
genes like Id1 and recruit co-repressors (Co-R) or co-activators (Co-A). I-Smads act 
inhibiting the signaling both at the receptor level and preventing Smad activation 
(Center, red). TGFβ also activates several non-canonical pathways (Left, Yellow). 
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However, TGFβ plays a dual role in cancer since in late-stage tumors the cellular 
machinery subverts the signaling pathway in order to promote the progression of 
the cancer [69]. In fact, alterations in TGFβ signaling in human cancers have been 
associated with the acquisition of all the cancer hallmarks, by losing of some of its 
normal functions (like growth inhibition) whilst retaining other effects that 
constitute a proliferative advantage (such as immunosuppression) as depicted in 
Figure 4. 
 
Figure 4 - All traditional cancer hallmarks are disrupted at variable extent, with 
insensivity to anti-growth signals comprising the most well described alterations. White 
boxes: TGFβ superfamily l igands, receptors, downstream effectors or in the responses 
exerted by TGFβ signaling pathway; Grey boxes: major cancer hallmark. TGFβ, 
transforming growth factor beta; IL-1, interleucin-1; IGF-1, insulin-l ike growth factor-1; 
CTGF, connective tissue growth factor; FGF, fibroblast growth factor; PDGF, platelet -
derived growth factor; TGFα, transforming growth factor alpha; PDGFR, PDGF receptor; 
EGFR, epidermal growth factor receptor; MAPK, mitogen-activated protein kinase; TGIF, 
transforming growth-interacting factor; VEGF, vascular endothelial growth factor; TERT, 
telomerase reverse transcriptase; pRb, protein retinoblastoma; LIP, liver -enriched 
inhibitory protein; ECM, extracellular Matrix; EMT, epithelial–mesenchymal transition.  
Concerning PCa, several alterations at different levels of the TGFβ signaling 
pathway have been defined. 
Ligands 
In PCa there is a dramatic increase in TGFβ1 mRNA and protein levels, which are 
correlated with high Gleason score, bone metastasis, angiogenesis and clinical 
outcome [14, 70]. In cancer, the TGFβ-induced growth inhibition is disrupted by the 
neoplasic surrounding environment [15]. It has also been shown that highly 
metastatic androgen-independent PCa cells have the ability to activate TGFβ [15] 
and that TGFβ can promote cancer growth, viability and aggressiveness [15, 71]. 
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These effects were not due to a direct increase on cell proliferation, but rather by 
effects in the host, namely increases in angiogenesis and invasiveness, 
accompanied by a suppression of immune response and cell adhesion [15, 71]. 
Notably, TGFβ is its most potent inducer; however it causes auto-induction at high 
concentrations only in malignant cells [72]. Even though most studies are centered 
in TGFβ, other ligands of the TGFβ superfamily may also play pivotal roles in PCa 
(e.g. Activins, BMP6, GDF15 and Nodal/BMP16) [73, 74]. 
Receptors 
Up to 30% of PCa cases have downregulation or absence of a TGFβ receptor [14]. 
Mutations of TGFβRII are common in lung and laryngeal cancers, but not in PCa 
[74]. Nevertheless, some PCa cells express a truncated TGFβRI mRNA transcript 
[75], lack a TGFβRII gene [76], have TGFβRs epigenetically downregulated [77, 
78], or carry some sort of TGFβRII mutation [79]. The fact that TGFβRI and 
TGFβRII are decreased in metastasis vs. primary tumors may indicate an active role 
for this alteration in cancer progression [80]. The decrease of TGFβRs in prostate 
tumor cells appears to lead to growth inhibition resistance, thus resulting in clonal 
expansion [12, 81-84]. On the other hand, distinct BMPRs appear to elicit different 
responses, with a shift from BMPR1B towards BMPRIA expression being associated 
with cancer, as the latter is associated with prostate growth [85, 86].  
Several studies have also reported the loss of TGFβRIII as the most common 
alteration during PCa progression being this alteration even more evident in 
metastasis [87]. Moreover, loss of TGFβRIII correlates with disease state, 
metastatic disease and PSA recurrence [87]. In a similar manner, endoglin (the 
other type III receptor) levels are lower in PCa cells vs. normal prostate cells and 
even lower in metastasis. Endoglin has been found to inhibit invasiveness, 
metastasis formation and motility while increasing cell adhesion, neovascularization 
and growth [88-91]. In contrast, its levels are higher in endothelial cells, being this 
associated with ongoing angiogenesis. Notably, endoglin may play a pivotal role 
regulating the fine equilibrium between Smad1/5/8 vs. Smad2/3 signaling [85, 89]. 
Effectors 
Smad alterations in PCa are also found, although not as extensively described as 
alterations in TGFβ ligands and receptors. In the initial stages of prostate tumor 
development, ALK2-Smad1/5/8 signaling is promoted to increase the growth and 
neovascularization, whereas in late-stage tumors there is a shift towards ALK5-
Smad2/3 signaling that leads to the acquisition of malignant capabilities, namely 
enhanced invasiveness, migration and metastasis formation [88, 90]. Smad4 
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promoter methylation has also been reported [92]. High levels of Ski, a co-
repressor of Smad2/3, were detected only in PCa cells [73] (Figure 5). 
 
 
Figure 5 - Main effects or alterations related to the TGFβ signaling pathway that drive to 
prostate cancer hallmarks are depicted in the scheme. Dark grey boxes: ligands, 
receptors or downstream effectors of the TGFβ signaling pathway; Light grey boxes: 
alteration in other targets (italics) or alteration in cancer cell hallmarks or effects 
(bold); Black arrows inside boxes: increase/decrease or activation/inactivation; Black 
arrows: effect or alteration. PSA, prostate-specific androgen; MMP-2, matrix 
metalloproteinase 2; MMP-9, matrix metalloproteinase 9; PA, plasminogen activator; 
pRb, protein retinoblastoma; BMP, bone morphogenetic protein; LTBP1, latent TGFβ 
binding protein 1; GDF15, growth differentiation factor 15; IGFBP3, insulin -l ike growth 
factor binding protein 3; GF, growth factors; GFR, growth factor receptor; MAPK, 
mitogen-activated protein kinase; BMPR, bone morphogenetic protein receptor; TGFβR, 
TGFβ receptor; ALK, activin receptor-l ike kinase; EGFR, epidermal growth factor 
receptor.  
I. 2. 2. TGFβ and androgens 
The relationship between TGFβ and androgens is also relevant. After androgen 
withdrawal, TGFβ and TGFβRs mRNA levels are upregulated, at least transiently 
[12, 70, 93]. Androgens have also been found to downregulate Smads expression 
and activation. DHT bounds to androgen receptor and this complex binds to active 
Smad 3, inhibiting the association of Smad 3 with SBE and, therefore, blocking the 
signal. Also, DHT leads to the inactivation of Sp1 suppressing its binding to TGFβRII 
promoter, thus decreasing TGFβRII levels [74, 94, 95]. It has been recognized that 
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the AR status determines the sensitivity of PCa cells to TGFβ-mediated apoptosis 
[96] and the ability to evade it is of paramount importance in the development of 
PCa [14]. 
I. 2. 3. TGFβ signaling pathway as a target in PCa 
TGFβ signaling pathway components have been regarded as possible targets for 
PCa therapy for several years [97]. Preclinical studies on direct targeting of TGFβ 
(ligand) using antisense approaches and antibodies, and indirect inhibition of its 
membrane receptors, provide promise for the potential therapeutic value of 
targeting TGFβ signaling. There is evidence that inhibiting the TGFβ signaling is a 
way to control tumor progression in cancer. The inhibition of TGFβRI kinase is also 
under study [98]. Moreover, genistein, currently in phase II of clinical trials, acts 
through activation of Smad 1, thus suppressing PCa cell invasion, in an ALK2-
dependent way [89]. Due to the prominent role of phosphorylation in TGFβ 
signaling and its deregulation in PCa, the targeting of phosphorylation systems of 
this pathway may represent a suitable way to address this issue. 
 
I. 3. Phosphorylation  
The phenomenon of protein phosphorylation was recognized more than 100 years 
ago; however, it was only in the 1950s that the first known example of “reversible 
protein phosphorylation” was identified, as regulating phosphorylase activation, 
thus concluding the research started 30 years before by Carl and Gerti Cori [99-
102]. Phosphorylation is the most important and common mechanism of acute and 
reversible regulation of proteins [103]. From one third to up to 70% of all proteins 
are regulated by this mechanism [104, 105], comprising circa 100 000 
phosphorylation sites [106]. In eukaryotic cells the majority of the phosphorylation 
events occur in three residues, namely serine, threonine and, lastly, tyrosine, in a 
1000:100:1 ratio [107]. However, histidine, arginine and lysine may also undergo 
phosphorylation [108]. Reversible protein phosphorylation is a ubiquitous and 
important intracellular control mechanism, being involved in almost all signal 
transduction pathways, cellular and physiological processes [109], in a variety of 
very distinct cellular processes, from photosynthesis [110] to cell cycle control 
[111] (Table 4). Although the importance of this process is particularly relevant in 
eukaryotic cells, it is so ubiquitous that it plays an important role even in 
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prokaryotic cells [112-114] and viral activity [115], thus demonstrating its 
paramount importance and high prevalence in life systems. Alterations in this 
process were naturally correlated with the development of several diseases [116, 
117], as listed in Table 4. Also, a number of naturally occurring toxins and 
pathogens also exert their effects by altering the phospho-state of proteins [117]. 
Table 4 - Phosphorylation is involved in a wide variety of molecular, cellular and 
physiological processes. Alterations in phosphorylation have been associated with the 
development of several pathologies. Mutations in kinases or phosphatases are the cause 
of several diseases or syndromes. 
Molecular 
Process 
Cellular 
Process 
Physiological 
Process 
Pathologies 
Genetic 
Disorders 
DNA 
replication 
Differentiation Immunity 
Alzheimer’s 
Disease 
Hirschsprungis 
disease 
Transcription Meiosis Embryogenesis 
Parkinson’s 
Disease 
Ataxia-
telangiectasia 
Translation Mitosis Injury healing Cancer Chraniosynostosis 
Enzymatic 
regulation 
Necrosis 
Hormonal and 
nervous control 
Diabetes 
Mellitus 
Li-fraumeni 
syndrome 
Splicing Apoptosis Angiogenesis Heart Failure 
X-linked 
myotubular 
myopathy 
 
Protein phosphorylation systems require four 
entities: a) a protein kinase; b) a protein 
phosphatase; c) a target protein and d) a 
phosphate (Figure 6). Protein kinases role is 
to catalyze the transfer of the gamma-
phosphate of ATP to the target protein, which 
becomes phosphorylated and changes its 
properties accordingly. This process is 
reversed by protein phosphatases (PPs) [118-
121]. 
At a biochemical level, protein activity,  subcellular localization, stability, half-life 
and interactions can be controlled by phosphorylation [122, 123]. The fact that 
multisite phosphorylation can occur, enables several of such effects to operate in 
the same protein and can also determinate the extent and duration of a response, 
being the key to signal integration [124]. The critical feature of phosphoamino acids 
Figure 6 - The mechanism of reversible 
phosphorylation. P - Phosphate 
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in proteins is that they act as new chemical entities that do not resemble any 
natural amino acid, and thereby provide a means of diversifying the chemical 
nature of proteins, inducing conformational changes through allosteric mechanisms, 
creating binding sites for molecules, altering the properties of 
association/dissociation of proteins among other effects [125-127]. 
There are over than 500 kinases encoded in the human genome [128], comprising 
2-3% of the human genome, thus representing one of the largest gene family [122, 
129]. Of these, nearly two thirds are Ser/Thr kinases, with tyrosine kinases 
comprising the remaining 33% [130]. Unlike kinases in which all belong to the 
same gene family, PPs are divided in several unrelated families (Figure 7). Tyrosine 
phosphatases (PTPs) can be either cytosolic (9 subclasses) or transmembranar (5 
subclasses) [131, 132]. All PTPs are monomeric and the domains that flank the 
catalytic domain control its activity and localization, with an unique catalytic 
mechanism [131]. Nowadays, circa 100 members of this family have been 
identified, thus making the number of PTPs similar to the number of tyrosine 
kinases [133]. Dual-specificity phosphatases are usually included in the PTPs 
family, in spite of their ability to act upon tyrosine, serine or threonine residues 
[131, 132]. Non-specific alkaline and acidic phosphatases can also be found, either 
in the intracellular level or in the extracellular milieu [134]. 
Ser/Thr PPs (STPPs) exert their effect by removing phosphate groups in serine or 
threonine residues. Initially, STPPs were divided according to 13 biochemical 
parameters [135]. This functional division was not reflected in the phylogenetic 
division. Three distinct gene families are now recognized: PPMs, FCPs and PPPs. 
PPMs (Mg2+ dependent) include PP2C, pyruvate dehydrogenase and relatives [136]. 
FCP family includes SCPs 1-3 and FCP1 phosphatases, which display specificity 
towards RNA polymerase II [137] (Figure 7). All members of the PPP superfamily 
have catalytic cores that share the same structural fold and catalytic mechanism, 
with the differences between these enzymes residing mainly in the solvent exposed 
loops that determine the shape and charge of the surface, and henceforth the 
affinity for ligands [105]. 
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Figure 7 - Phylogenetic division of PPs. 
Surprisingly, only 13 genes encode PPPs catalytic subunits, which have to 
counteract the effects of nearly 350 Ser/Thr kinases [138]. The discrepancy 
between the number of STPPs and kinases (circa 20 times fewer STPPs) is 
answered by the different strategies of achieving regulated specificity [139]. While 
in the case of Ser/Thr kinases diversity is achieved by gene duplication, in the case 
of STPPs it is achieved by their unparalleled ability to form stable protein 
complexes. This is due to the existence of a variety of different holoenzymes, each 
with its own substrates and mode of regulation [105, 138, 140]. 
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I. 4. PPP1  
PPP1 (phosphoprotein phosphatase 1) and PPP2 are major PPs that account for 
more than 90% of dephosphorylation events. In fact, 650 different PPP1 complexes 
and 70 PPP2 holoenzymes are taught to be contained in mammals, thus indicating 
that PPP1 catalyzes the majority of dephosphorylation events in eukaryotic cells 
[105, 138, 140]. Naturally, PPP1 has been associated with the regulation of a 
number of signal transduction pathways, cellular and physiological processes and 
its deregulation with several diseases, namely cancer, male infertility, 
neurodegenerative and cardiovascular diseases [116, 141, 142]. 
In mammals, the PPP1 catalytic subunit (PPP1C) is encoded by 3 highly related 
genes (PPP1CA, PPP1CB and PPP1CC). Also, alternative splicing of PPP1CC gene 
generates the ubiquitously expressed PPP1CC1 isoform and the testis-enriched and 
sperm specific PPP1CC2 isoform [140, 143]. As with other PPPs, PPP1 is very 
unspecific in vitro and usually cannot be differentiated by substrate specificity or 
ability to interact with regulatory subunits. Only minor differences in N- and C-
terminus exist between the isoforms (PPP1CC1 and PPP1CC2 only differ at the C-
terminus), with an overall identity of over 90% [130, 139]. However, in vivo it 
displays an exquisite specificity of targets and functions [139]. Several aspects 
contribute to this enhanced specificity in vivo. Although all isoforms (except for 
PPP1CC2) are ubiquitously expressed, some differences in the expression levels are 
found between the tissues (Table 5) and even within the same tissue [144]. Also, 
minor differences in terms of subcellular localization are also described (Table 5).  
Table 5 - Subcellular localization and tissue distribution of the PPP1C isoforms  
PPP1C 
isoform 
Subcellular localization 
Tissue distribution 
Nuclear During Mitosis 
PPP1CA Nuclear matrix Centrosomes Ubiquitous, abundant in brain 
PPP1CB Chromatin Chromosomes Ubiquitous, abundant in liver and kidney 
PPP1CC Nucleolus Mitotic spindle 
Ubiquitous, abundant in brain, small 
intestine and lung (PPP1CC2 is testis-enriched 
and sperm-specific) 
 
Nonetheless, as with other PPPs, the specificity is mostly achieved by the 
interaction with regulatory subunits, or PIPs (PPP1 interacting proteins)  [142]. 
Over than 200 PIPs have been identified [116], but many more remain to be found, 
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as well as multiple proteins that interact with PPP1 in an indirect manner. 
Preferential binding of PIPs to individual PPP1C isoforms has also been described 
[138, 139, 145]. These regulatory subunits have been classified into 4 classes 
(Table 6), regarding its effects in PPP1. Another level of regulation is achieved by 
post-translational modifications or allosteric regulation of both PPP1C and PIPs, 
which can induce conformational changes that modulate their activity or the 
interaction between PIPs, PPP1C and the substrate [138]. The exquisite specificity 
of PPP1 in vivo is also explained by the fact that some PIPs are expressed in a cell 
type-dependent manner, accounting for cell type-specific PPP1 activity [105]. 
Table 6 - Functions of PIPs and the effect exerted.  
Function Example Effect 
Substrate BRCA1 Activation 
Aurora-A Inactivation 
Ikaros Stabilization 
Targeting GADD34 Targeting to ER 
URI Targeting to 
Mitochondria 
NOM1 Nucleoli 
Activity 
modulation 
PPP1R2 Inhibition of PPP1 
Unclassified HOX11 Unkown 
 
As with other PPPs catalytic subunits, PPP1C is highly abundant but does not exist 
as free monomers in eukaryotic cells, being always associated with one or two PIPs 
[139]. Therefore, rather than seeing PPP1C as a single pleiotropic or promiscuous 
phosphatase, it should be considered as a large family of biochemically diverse 
holoenzymes, with individual PPP1C-PIPs displaying high specificity, even though 
sharing a common catalytic subunit [138]. 
I. 4. 1. PPP1 binding motif 
The analysis of known PIPs have led to the establishment of a PPP1-binding motif, 
the well-known RVxF, which is found in 70% of PIPs. This sequence is degenerate, 
with the redefined consensus motif being K/R V/I x F/W, where x is any residue 
other than Phe, Ile, Met, Tyr, Asp, or Pro. Mutations in the hydrophobic residues 
(V/I) or aromatic residues (F/W) are sufficient to weaken or disrupt binding of 
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regulatory subunits to PPP1C. The residues that are necessary for PIP-PPP1C 
binding, particularly 287-293, are invariant in all isoforms. Sequences flanking this 
motif may play a role in defining the affinity or specificity for a PPP1C isoform [105, 
138, 139]. Binding to RVxF does not cause important conformational changes of the 
catalytic subunit and does not have a major impact effect on its activity. In fact, 
RVxF may act as an anchor for PPP1C, enabling regulatory subunits to make 
additional contacts with the phosphatase in an ordered and cooperative manner. 
The absence of one of these associations can have either have no effect, weaken or 
disrupt the association, depending on the strength of the remaining interactions 
[139]. As previously indicated, not all PIPs display the RVxF motif, with several 
other more uncommon PPP1C-binding motifs being identified throughout the years 
(Table 7). 
Table 7 - PPP1 Binding Motifs. Note: SILK motif needs to be from 7 to 107 aa of distance 
from the RVxF motif;X(0,1) is any aa, present or absent; {P} is any aa except P.  
Motif Sequence PIPs 
RVxF [RK]-X(0,1)-[VI]-{P}-[FW] PPP1R8, PPP1R10 
SILK K-[GS]-I-L-[RK] NOM-1, WBP 
MyPhoNE R-X-X-Q-[VIL]-[KR]-X-[YW] 
PPP1R12A, 
PPP1R12B 
PPP1R2 
degenerate 
motif 
R-[KR]-X-H-Y PPP1R2 
Apoptotic Motif 
[RK]-X(0,1)-[VI-]X-F-X-X-[RK]-
X-[RK] 
Bad, Bcl-2 
Other motifs 
RARA PPP1R15A 
RNYF iASPP 
YSNEDYDR  sds22 
 
I. 4. 2. Role of PPP1 and other phosphatases in TGFβ signaling 
 
As previously stated, TGFβ-induced signaling relies in a series of phosphorylation 
events that are triggered by the binding of the ligand to TGFβRII. Since TGFβRI and 
TGFβRII are Ser/Thr Kinases, an increasing number of protein phosphatases, 
particularly of the STPP family, have been reported to regulate the TGFβ pathway 
through interactions with both receptors and Smad proteins [146]. It is well known 
that PPP2 inhibits TGFβRI, BMPRII and the R-Smads, either directly or via its 
regulatory subunits. The role of other phosphatases, including PPM1A, FCPs, SCPs 
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and Dual-Specificity Phosphatases, in TGFβ signaling regulation has also been 
described [146]. PPP1 acts as a negative regulator of TGFβRs through its binding to 
Smad anchor for receptor activation protein (SARA). SARA presents PPP1 to ALK5 
receptor promoting its dephosphorylation and consequent signal attenuation [147]. 
This targeting involves the inhibitory Smad7, and another PIP, GADD34 
(PPP1R15B). It has also been shown that Smad7 recruits PPP1C to ALK1, inhibiting 
Smad 1/5/8 dependent pathway [148, 149]. The PIP that recruits PPP1 to ALK1 still 
needs to be elucidated, however, a Smad anchor for BMP signaling called Endofin 
was recently discovered. In a similar way of what happens to SARA, PPP1 also binds 
to Endofin and GADD34 to dephosphorylate the ALK3 and ALK6 receptors but 
without any intervention of the inhibitory Smad7 [150]. 
I. 4. 3. Role of phosphorylation and PPP1 in PCa 
Constitutive activation of oncogenic kinases is one of the hallmarks observed in 
cancer cells, driving uncontrolled cell proliferation, invasion and metastasis . 
Transmembrane kinases, such as epidermal growth factor receptor (EGFR) and 
platelet-derived growth factor receptor (PDGFR), and cytoplasmic kinases, such as 
Raf, MAPK and Akt are mutated or constitutively activated in several types of 
human cancer, including PCa. For example, an increased Akt signaling, a Ser/Thr 
kinase involved in the control of cell size/growth, proliferation and survival  has 
been associated with poor clinical outcome in a variety of tumors [152, 153]. In 
PCa it is commonly observed the loss of the tumor suppressor gene that encodes 
PTEN, a lipid phosphatase that negatively regulates PI3K/Akt signaling by 
dephosphorylation of phosphatidylinositol 3,4,5 phosphate, either by mutation or by 
suppression via microRNA miR-153 [154]. PTEN loss enhances the activation of 
several signaling pathways which are normally upregulated in PCa, including 
PI3K/Akt and MAPK, resulting in the acquisition of malignant characteristics such as 
reduced apoptosis, increased proliferation and metastasis formation [155]. In PCa, 
PPP1 and PPP2 also act as tumor suppressors. 
PPP1 has been associated to PCa either directly or via its PIPs. PPP1 directly 
dephosphorylates and attenuates the two major tumor suppressors, p53 and pRb, 
which deregulation has been associated with PCa [156-158]. PPP1 also 
dephosphorylates Akt, regulating its activity and also its downstream targets, 
promoting apoptosis (Xiao, et al., 2010). Several PIPs have also linked PPP1 to PCa, 
such as NIPP1 and AR. PPP1/NIPP1 complex has been recently described as a 
regulator of cancer cell migration, specifically in PCa cells [159]. Chen and 
colleagues have shown that AR and PPP1 interact, and that PPP1 inhibition 
enhanced AR degradation. On the other hand, PPP1 overexpression increased AR 
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expression and transcriptional activity in PCa cells [160]. In similar ways, many 
other PIPs or pathways regulated by PPP1 associated with PCa have been described 
like Apaf-1, Aurora kinases, BRCA1, Bcl-2, CDC25, and caspases [161-168] 
I. 4. 4. PPP1 and PIPs as molecular targets 
Protein phosphatases represent attractive targets for when a deregulation of the 
phosphorylation system is present, such as cancer. PPP1 inhibition is usually 
regarded as not viable due to PPP1 ubiquitous expression and pleiotropic effects, 
which leads to toxicity. For these reasons, it is rather more suitable to target PIPs 
instead of protein phosphatases directly as they may be more event, tissue and 
subcellular compartment specific [169]. Nowadays, two targeted PPP1-PIP 
complexes have been described and approved by FDA. The levels of PPP1-GADD34 
complex are diminished in cells treated with salubrinal, a small molecule that 
protect the cell from ER-stress-induced apoptosis [170]. The other complex 
involves PPP1 and histone deacetylases (HDACs) and is an attractive target to 
antitumor drugs. Trichostatin A, for example, disrupts the interaction between PPP1 
and HDAC6 in glioblastoma and PCa cells, ultimately leading to the suppression of 
the AKT signaling pathway, usually upregulated in PCa. The introduction of 
oligonucleotide antisense therapy may contribute to an even more specific 
targeting, thusly producing less side-effects [170].   
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I. 5. TCTEX1D4 - Dyneins and the T-
complex 
The trafficking of membranous vesicles and particles inside the cell is a process of 
great importance in cell physiology [171]. Two general movements are described, 
one towards the cell membrane or anterograde, in which kinesins are the motor 
proteins, and another towards the nucleus or retrograde, in which dyneins are the 
driving force [172]. Dyneins are massive molecular motor complexes of 1-2 MDa 
that generate force towards the minus-end of microtubules [173] and are divided 
into axonemal (associated with cilia and flagella) and cytoplasmic [174]. These 
complexes are composed of 4 subunits: a) heavy chains, an ATPase that binds to 
the microtubule and drives cargo movement; b) intermediate chains, which 
mediates cargo binding and regulates the motor activity; c) light intermediate 
chains, mediates cargo binding to the dynein; d) light chains (DLC), the unit for 
cargo binding and specificity. Cytoplasmic dyneins are involved in several motile 
dynamic processes such as meiosis, mitosis and maintenance of the Golgi 
apparatus. Dyneins have been found to be regulated by phosphorylation [173]. 
Regarding DLCs, 3 families have been defined, namely LC8, Roadblock/LC7 and 
DYNT1/TCTEX1. TCTEX1 and the related TCTEX2 were firstly identified in the mice 
t-complex [173]. The mouse t-complex is localized in chromosome 17 and 
corresponds to a naturally occurring variant [175]. The t-haplotypes result from a 
series of inversions and mutations that lock together a set of genes with effects in 
embryonic differentiation, male fertility and chromosome behavior [175, 176]. 
I. 5. 1. TCTEX1D4 Protein 
T-complex testis expressed protein 1 domain containing 4 (TCTEX1D4), a DLC from 
the TCTEX1/DYNLT1 family, has been recently identified as a new PIP in testis 
library [177-180]. TCTEX1D4 has 221 amino acids, with a predicted molecular 
weight of 23 352 Da and is encoded by a 2-exon gene in 1p34.1 locus. It has two 
distinct domains: the first 95 amino acids account for the disordered domain, with 
the remaining 126 residues constituting the globular domain. The globular domain 
is similar to the globular domains of the DYNLT1 family, with 2 α-helixes and 4 β-
strands. Using bioinformatics, many putative serine phosphorylation sites have 
been identified. Surprisingly, no threonine or tyrosine phospho-sites were identified, 
thus leading to the hypothesis that TCTEX1D4 function is mainly regulated by 
serine phosphorylation mechanisms. Moreover, a N-glycosylation site (205-200) 
and several binding domains were identified: APC/C D box (28-36), cyclins (161-
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165) and MAPK (167-176). As with most PIPs, the RVxF motif (RVSF) is found in 
TCTEX1D4, in the N-terminus (90-93). It was found to interact with all PPP1 
isoforms and it appears to be important to complex formation and function. 
Nevertheless, the mutation of RVSF to AAAA only partially decreased the binding 
ability (35%), probably because the proline-rich surrounding environment forces 
the structure to the RVSF motif, even when mutated. Regarding TCTEX1D4 tissue 
expression, the EST profile in various species has localized it in the female 
reproductive tract (ovary, oviduct, placenta, uterus and embryo), head 
(hypothalamus, brain, striatum, tongue) and lung. Concerning subcellular 
localization studies in testis and sperm, TCTEX1D4 is present in the cytoplasm 
(near cell-cell junctions, MTOC and microtubule-like structures) and in the cell 
nucleus. The interaction with PPP1 was found to occur in the nucleus and in the 
MTOC. [177, 179].  
Regarding possible functions, TCTEX1D4 has been proposed to be a player in TGFβ 
signaling pathway, cell-to-cell junctions and microtubule dynamics. The existence of 
binding sites for APC/C, cyclins and MAPK has also raised the possibility of playing a 
role in proliferation, differentiation and cell cycle regulation. Regarding microtubule 
dynamics it is at least partially responsible for PPP1 targeting to MTOC. In terms of 
TGFβ signaling, TCTEX1D4 has been found to bind to two TGFβ receptors which 
downregulation has been associated with PCa, Endoglin and TβRII, inhibiting TGFβ 
2/3 signaling. In terms of the interaction of TCTEX1D4 with Endoglin, it has been 
found to occur mostly in the cell membrane, cellular protrusions and only rarely in 
vesicles. Of particular interest, it has already been shown that specific Smad 
pathways may require specific DLC [181] which can play a pivotal role in defining 
the intracellular signal transduction pathway, of which, ultimately, opposing effects 
of TGFβ may arise. PPP1 is known to bind and dephosphorylate intermediate chains, 
so binding to TCTEX1D4 is most likely to facilitate the access to intermediate 
chains, thus regulating the dynein complex function. The flexible arm of the 
disordered N-terminus is thought to help the binding of TCTEX1D4 to diverse 
regulatory proteins and cargoes [178, 179]. The unraveling of TCTEX1D4 
interactome may be of great importance in understanding its role in the cell. 
With this work, it is intended to unveil the role of the recently identified PIP 
TCTEX1D4 in TGFβ signaling and in PCa. It was proposed that TCTEX1D4 might act 
as a DLC in this system. Ultimately, TCTEX1D4-PPP1 may represent a suitable 
target for PCa therapy, as the targeting of very specific PIPs represents a good 
strategy in cancer therapy and TGFβ signaling pathway is a desirable target in PCa.  
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II. Aims 
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The main objectives of the work were as it follows: 
 To establish several cell lines representing normal, androgen-dependent 
malignant and androgen-independent malignant prostate cells 
 To demonstrate the presence of TCTEX1D4 in normal and malignant 
prostate cells 
 To identify TCTEX1D4/PPP1 complexes in normal and malignant prostate 
cells 
 To perform subcellular and tissue localization studies of TCTEX1D4, PPP1 
and other proteins associated with TGFβ signaling  
 To identify variations in the expression levels of TCTEX1D4 and PPP1 
between normal and malignant prostate cells 
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III. Materials and Methods 
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The composition of all solutions is presented in Appendix I. 
III. 1. Cell culture 
The following cell lines were used: RWPE-1, LNCaP, DU 145 and PC3. All cells were 
tested for the presence of mycoplasma and results were negative. Cells were split 
every week and medium renewal took place 2 to 3 times a week. Cell handling 
occurred according to the instructions presented by ATTC datasheets. Briefly, 
medium renewal occurred as follows: medium was removed by an aspiring pipette, 
cells were briefly washed with PBS and a suitable amount of medium was added 
(10 ml in 100 mm Petri dishes). To split the cells, medium as removed and cells 
washed with PBS, upon which a suitable amount of 0.25% trypsin-0.53mM EDTA 
was added (1-2 ml, in 100 mm Petri dishes). After cells have detached, a trypsin 
inhibitor solution (usually a 10% FBS-PBS solution) was added (8-9 ml, in 100 mm 
Petri dishes) and cells centrifuged for 3 minutes at circa 125 g. Then, supernatant 
was discarded and cells were re-suspended in 10 ml of fresh medium. 
Subcultivation ratio was usually between 1:10 and 4:10. Cells used in the 
experiments had between 10 and 30 passages. LNCaP and PC-3, and DU 145 cells 
were kind gifts from Dr. Rui Medeiros (IPO Porto) and Dr. Tobias Lunge (University 
Medical Center Hamburg-Eppendorf), respectively. RWPE-1 cells were acquired 
from ATCC. PBS, RPMI 1640, K-SFM and FBS were acquired from Invitrogen. More 
information about to the cell lines and cell culture conditions are in Tables 10 and 
11. 
Table 10 - Cell lines used and culture conditions. NOTE: Occasionally, 20% FBS was 
used in LNCaP cells to enhance adhesion. In the University Medical Center Hamburg -
Eppendorf, cells were grown using FCS instead of FBS. K-SFM: Keratinocyte serum-free 
medium; EGF – Epidermal growth factor; BPE – Bovine Pituitary Extract; AA –
penici ll in/streptomycin.  
Cell Line Complete Medium Adherent Growth Conditions 
RWPE-1 
K-SFM with EGF (0.15 ng/ml), BPE 
(25 μg/ml) and 1% AA (v/v) 
Yes 37º C / 5% CO2 LNCaP 
RPMI 1640 with 10% (v/v) FBS and 
1% AA (v/v) 
DU 145 
PC3 
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Table 11 - Cell l ines characteristics regarding malignity, androgen responsiveness and 
site of metastasis upon extraction 
Cell Line Characteristics Androgens Tumorigenicity 
Site of  
metastasis 
RWPE-1 Normal Epithelial Cells Sensitive None - 
LNCaP Prostate cancerous epithelial cells Sensitive Low Lymph node 
DU 145 Prostate cancerous epithelial cells Insensitive Moderate Brain 
PC3 Prostate cancerous epithelial cells Insensitive High Bone 
 
III. 2. Tissue Samples 
Tissue samples used and information regarding their origin and preservation are 
found in Tables 12 and 13. 
Table 12 - Tumor tissues and information regarding original cell line, type of cancer it 
represents and fixation method. PFA – paraformaldehyde solution (4%) 
Originary cell line Type of Cancer Fixation 
PC 3 
Prostate Cancer 
PFA + Paraffin 
OR Flash 
Frozen 
LNCaP 
DU 145 
LuCaP 23.1 
OH3 Small Lung Cell 
Carcinoma 
PFA+Paraffin 
H69 
 
Table 13 - Normal tissues and information regarding origin of the samples and fixation 
method. PFA – Paraformaldehyde solution (4%); SG – Sucrose gradient; BPH – Benign 
prostatic hyperplasia 
Tissue Origin Fixation 
Prostate 
Surgical procedure in 
patient with BPH 
Flash Frozen OR PFA + SG + 
Cryopreservation 
Lung Biopsy PFA + Paraffin 
Placenta Caesarian birth 
Flash Frozen OR PFA + 
Paraffin OR PFA + SG + 
Cryopreservation 
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III. 3. Antibodies 
For the present work the antibodies against the following proteins were used: 
TCTEX1D4 (C -terminal), TCTEX1D4 (N-terminal), PPP1CA, PPP1CC, Endoglin (CD 
105), Smad 1, Smad 2 and Smad 3. Secondary antibodies against Mouse and 
Rabbit were also used. A detailed description is present in Tables 8 and 9. 
Table 8 – List of primary antibodies used and information regarding origin, dilution 
range used and host. WB – Western Blot and IF - Immunfluorescence 
Target Company Reference 
Dilution Range 
(WB) 
Dilution Range 
(IF) 
Host 
TCTEX1D4 (C-
terminal) 
Homemade CBC8C 1/50-1/1000 1/150-1/500 Rabbit 
TCTEX1D4 (N-
Terminal) 
Sigma-Aldrich RP11269F19.9 1/50-1/1000 1/150-1/1000 Rabbit 
PPP1CA Homemade CBC2C 1/2500 - Rabbit 
PPP1CC Homemade CBC3C 1/5000 1/500-1/1000 Rabbit 
Endoglin Abcam ab114052 1/1000 1/300-1/500 Mouse 
Smad 1 
LifeSpan 
BioSciences 
LS-C133298 1/300 1/50-1/300 Mouse 
Smad 2 
Novus 
Biologicals 
H00004087-
M05 
1/500 1/50-1/300 Mouse 
Smad 3 Sigma-Aldrich SAB1404037 1/300 1/100-1/500 Mouse 
Table 9 – List of secondary antibodies used and information dilution range used. WB – 
Western Blot and IF - Immunfluorescence 
Target Designation Dilution Range (WB) Dilution Range (IF) 
Anti-Rabbit Odissey 680 nm 1/5000 - 
Anti-Mouse Odissey 800 nm 1/5000 - 
Anti-Rabbit TrueBlot 1/1000 - 
Anti-Rabbit Cy3-labeled - 1/500 
Anti-Rabbit 
Texas Red-
labeled 
- 1/300 
Anti-Mouse Cy3 - 1/500 
Anti-Mouse 
Alexa 488-
labeled 
- 1/300-1/500 
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III. 4. Primers 
Primers for GAPDH, β-Actin, HPRT, PPP1CC and TCTEX1D4 were retrieved from the 
literature or designed using the Universal ProbeLibrary (Roche) or the Primer-Blast 
tool from NCBI, following the instructions required to design primers suitable for 
qPCR, including the fact that primers should span exon-exon junctions. Primers 
were synthesized at Eurofins MWG Operon. More information regarding is present in 
the Appendix II. 
III. 5. Western Blotting 
Sample preparation 
The cell medium was removed; cells were washed with PBS and samples collected 
by adding boiling 1% SDS and gentle scrapping. The lysates were collected to 
microtubes and then boiled for 10 minutes and sonicated for 20 seconds. 
BCA protein assay 
The protein content of the samples was determined using BCA protein assay 
(Pierce). The standards for quantification were prepared as described in the table 
14. 
Table 14 - BCA Standards. BSA, bovine serum albumin; WR, Working reagent (to 
prepare WR 50 pars of BCA reagent A was mixed with 1 part of reagent B).  
Standards BSA (μl) 1%SDS (μl) Protein mass (μg) WR (ml) 
P0 - 50 0 1 
P1 1 49 2 1 
P2 2 48 4 1 
P3 5 45 10 1 
P4 10 40 20 1 
P5 20 30 40 1 
 
Reactions were initiated by adding 1 ml of WR to 50 μL of each sample. The 
standards and samples were incubated at 37ºC for 30 minutes. The absorbance 
was then measured at 562 nm and a standard curve was prepared by plotting the 
value for each BSA standard against its concentration. Using this curve the protein 
concentration of each sample was determined. 
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SDS -PAGE 
Samples (usually corresponding to 100 μg of protein) were subjected to SDS 
polyacrylamide gel electrophoresis (SDS-PAGE). Samples were prepared and 4x 
loading buffer added. Proteins were then resolved on a SDS-PAGE of variable 
percentage, most suitable to each case. Gels were run at 200V for approximately 1 
hour. 
Immunoblotting 
After electrophoresis, proteins were transferred onto a solid support, while keeping 
their positions and then visualized with specific antibodies. Proteins were 
transferred to nitrocellulose membranes at 200 mA for circa 2 hours. 
Immunoblotting of the transferred proteins was performed by initially blocking any 
possible non-specific binding of the primary antibody by immersing the membrane 
in 5% non-fat milk in TBS-T (blocking solution) for nearly 1 hour with shaking. 
Then, membranes were incubated with primary antibody (diluted in 3% non-fat 
milk, in TBS-T) and left for 1 hour to overnight depending on the antibody being 
used. 
After removing the primary antibody, the membranes were washed three times, 10 
minutes each, in TBS-T and the primary antibody was detected with a solution of 
the appropriate secondary antibody, diluted in 3% non-fat milk, in TBS-T for 1 hour 
with shaking. Membranes were again washed three times, for 10 minutes and the 
secondary antibody detected using either a chemiluminescence detection system 
(ECL; Amersham Pharmacia Biotech) or using the Odyssey detection System, 
accordingly to the secondary antibody used. In the first case, excess solution was 
drained by touching the edge of the membranes against tissue paper and the 
membrane was gently wrapped with cling-film, eliminating all air bubbles. In the 
dark room, the membrane was placed in a film cassette and an autoradiography 
film was placed on the top. The cassette was closed and the blot exposed over a 
certain period of time. The film was then removed and developed in a developing 
solution, washed in water and fixed in fixation solution. In the situations in which 
Odyssey detection system was used, membranes were scanned at 680 or 800 nm 
wavelength of excitation according to the secondary antibody used. 
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III. 6. Immunoprecipitation and Co-
Immunoprecipitation 
Sample Preparation 
Usually two confluent 100 mm Petri dishes for each cell line were used. Cells were 
washed with PBS and samples lysed with RIPA lysis buffer (Millipore) containing 
protease inhibitors. The retrieving of the cells was done with a scrapper to a 
microtube, immediately put on ice. Samples were sonicated three times for 10 
seconds and centrifuged at 16 000 g at 4ºC during 15 minutes. The pellet was re-
suspended in SDS 1% becoming the Pellet Fraction. A small fraction of the 
supernatant was retrieved to a microtube originating the Soluble Fraction. The 
remaining supernatant was used in the following steps. 
Pre-Clearence 
The storage solution was removed from 20 μl of re-suspended dynabeads (Protein 
G Dynabeads, from Invitrogen) which were then washed 3 times with 500 μl of 
PBS. These were incubated 1 hour with rotation at 4ºC. After that, dynabeads were 
separated from the sample using a magnet (Dynal MPC). Dynabeads were re-
suspended in SDS 1% thus forming the Dynabeads Bound Fraction. A small fraction 
of the supernatant was retrieved and labeled as Dynabeads Unbound Fraction. The 
remaining was used in the subsequent steps. 
Precipitation 
Samples from pre-clearance were incubated with primary antibody (3-5 μg) 
overnight with rotation at 4ºC. Re-suspended and washed dynabeads were used to 
incubate with the samples for 1h30 with rotation at 4ºC. An Unbound 
Immunoprecipitation Fraction was then retrieved upon dynabeads capture with the 
magnet. The remaining of the supernatant was discarded. Dynabeads were washed 
three times. Firstly, 100 μl of PBS was used and an aliquot was kept (Wash 
Fraction). The other 2 washing steps were carried out with 500 μl of PBS. The 
beads were then re-suspended in SDS 1% and boiled for 5 minutes, generating the 
Immunoprecipitation Fraction. 
Fractions Preparation 
Loading buffer 4x was added to all samples. Fractions were then boiled for 10 
minutes. 
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SDS -PAGE 
Samples were subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE) as 
previously described. 
Immunoblotting 
Samples were then immunoblotted as previously described. Notice that the 
difference between Immunoprecipitation and Co-Immunoprecipitation only occurs 
at this point. In the first, the primary antibody is the same (or against the same 
protein) which was used in the precipitation step. In the case of a Co-
Immunoprecipitation the primary antibody used is against other protein, expected 
to interact and be bound to the one precipitated. 
III. 7. Immunocytochemistry 
Sample Preparation 
A suitable number of cells were seeded into 6- or 12-well plates. Occasionally, a 
previous treatment of the coverslips was performed by briefly rinsing them with 
poly-L-ornithine (0.1 mg/ml, Invitrogen) in order to increase adherence. Cells are 
then left to rest until they are adherent to the coverslips, at least 24h. 
Immunostaining 
Afterwards, medium was removed and cells were gently washed with PBS. Cells 
were then fixed by adding paraformaldehyde 4% for 15 minutes. Cells were then 
treated with 0.2% Triton X-100 in PBS for 15 minutes. Cells were then blocked with 
a blocking solution, either a 3% solution of BSA in PBS or Immunoblock (Roth). 
Cells were then incubated with the primary antibody diluted in the blocking solution 
during 1 hour in a dark and wet chamber. Cells were then washed three times with 
PBS, followed by incubation with the secondary antibody, under the same 
conditions as the ones used for the primary antibody. DAPI is usually added to the 
secondary antibody dilution, however occasionally it was also used mounting 
medium with nuclear staining compound. After cells were washed three times with 
PBS the coverslips were mounted in the slides using a fluorescence mounting 
medium (either Mowiol, VectaShield or Dako were used). Slides were stored 
protected from the light at 4º C. 
Image acquisition 
Images were acquired using either fluorescence or confocal microscopes, with the 
assistance of Dr. Luís Korrodi, Dr. Georg Lüers and Dr. Ann-Kristin Brauns. The 
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devices used were a Olympus IX-81 inverted epifluorescence microscope and a 
Nikon A1 Confocal Laser Microscope. 
III. 8. Immunohistochemistry 
Sample Preparation 
Three types of tissue samples were used: a) tumors generated in nude mice, via 
implantation of human cancer cell lines and further retrieval of the samples; b) 
normal placenta tissue previously prepared; c) fresh samples of normal tissues, 
namely from placenta and prostate. The first two types of samples were kindly 
provided by Dr. Tobias Lunge at the University Medical Center of Hamburg-
Eppendorf. Fresh samples were treated by 3 different methods: a) flash frozen in 
liquid nitrogen; b) briefly treated with a 4% solution of paraformaldehyde in PBS, 
followed by paraffin embedding and c) treatment with a 4% solution of 
paraformaldehyde in PBS, followed by a prolonged sucrose gradient treatment. In 
this treatment, samples were  submerged in a 10% sucrose solution for 1 hour, 
another hour in a 15% sucrose solution and then samples are left overnight at 4ºC 
in a 30% sucrose solution. Afterwards, samples were submersed in cold 2-
methylbuthane and transferred into liquid nitrogen. Cryosections (5 μm) of the 
cryopreserved samples were prepared using Leica CM 3050 into Superfrost Plus 
(Hecht Assistant) slides using TissueTek (Sakura) as embedding material. Samples 
were stored at -20ºC or at -80ºC (long-term storage). The paraffin-embedded 
samples used were already sectioned. 
Immunostaining 
Firstly, in paraffin-embedded tissues paraffin was removed using the standard 
protocol of deparaffinization in a Varistain 24-4 (Thermo) device. On the other 
hand, cryopreserved samples were initially treated for 30 minutes with 0.2% TBS-
TT. The next steps took place regardless of the type of sample and all incubation 
steps take place in a dark and wet-chamber, in order to avoid drying of the 
samples.  
Tissues were blocked for 30 minutes with Immunoblock, after which were incubated 
with the primary antibody diluted in Immunoblock for 1 hour. Afterwards, samples 
were quickly washed twice with TBS-T and once with TBS, followed by 1 hour of 
incubation with the secondary antibody, diluted in the Immunoblock and with DAPI 
added. After another similar washing step, samples were mounted with Mowiol or 
Dako fluorescence mounting medium and stored in a cold and dark room. 
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Image acquisition 
The devices used were an Olympus IX-81 inverted epifluorescence microscope and 
a Nikon A1 Confocal Laser Microscope with the assistance of Dr. Luís Korrodi, Dr. 
Georg Lüers and Dr. Ann-Kristin Brauns. 
III. 9. RT-qPCR 
Sample preparation 
RNA samples from DU 145, LNCaP and PC3 cell lines were kindly provided by Dr. 
Tobias Lunge. Prostate and Placenta RNA samples were extracted from fresh flash-
frozen samples. 
RNA extraction 
RNA was extracted from prostate and placenta tissues using the RNeasy Midi Kit 
(QIAGEN), following the instructions provided. Briefly, a small amount of the tissue 
(up to 250 mg) was kept frozen in liquid nitrogen and disrupted mechanically with a 
mortar and pestle followed by addition of a lysis buffer. After homogenization of the 
sample, a series of centrifugation steps through the RNeasy Midi Column using 
supplied buffers steps takes places and lastly the RNA is retrieved from the column 
centrifuging with RNase-free water. Long-term storage at-80 ºC. 
Reverse transcription 
The quality and concentration of the RNA samples from DU 145, LNCaP, PC3, 
Prostate and Placenta were assessed using the Nanodrop ND-1000 
spectrophotomer device. Following that, reverse transcription was performed using 
RT2 First Strand Kit (QIAGEN) according to the instructions provided. Briefly, 1μg of 
RNA was used for the procedure and genomic DNA elimination buffer was used to 
increase the purity of the cDNA retrieved. Afterwards, a reverse transcription 
cocktail was prepared and incubated with the RNA during 15 minutes, at which 
point the reaction was terminated and nuclease-free water was added. 
Characterization of the cDNA in terms of concentration and purity was then 
performed using the Nanodrop ND-1000 device and samples were stored in -20ºC. 
qPCR 
A 96-well plate was used to sample the diverse components. A suitable amount of 
the forward and reverse primers (both between 0.2-0.6 μl of the 0.1 μmole 
solution) and cDNA (circa 150 ng) are mixed with 5μl of LCMM and qPCR-grade 
water is added to a final volume of 10 μl. Usually blanks for each primer pair 
(without the cDNA) and totally empty wells were included. The qPCR reaction and 
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quantification took place in the Roche LightCycler 480. The general protocol was as 
it follows: 1 – 1 cycle of 5 minutes of pre-incubation at 95º; 2 – 45 cycles of 
amplification (10 seconds at 95ºC), annealing (10 seconds at 60ºC) and extension 
(10 seconds at 72ºC); 3 – Melting curves. 
Statistical analysis 
Results were analyzed using the Relative Expression Software Tool – Multiple 
Condition Solver – version 2, which calculates the relative expression in qPCR using 
a pair-wise fixed reallocation randomization test. 
III. 10. Mass Spectrometry 
Immunoprecipitation was performed as previously described. IP fractions were then 
run through a 15% SDS-PAGE at 200V for circa 1 hour. Afterwards, the gel was 
fixed during 30 minutes using Fixing Solution and then washed with water. Then, 
the gel was stained for 30 minutes with Coomassie Blue Staining Solution upon 
which the gel was quickly washed with water and then submerged into Distaining 
Solution for 30 minutes. Distaining Solution is then renewed and gel is let to detain 
overnight, with renewal of the Distaining Solution being performed if necessary. All 
these steps take place with agitation. 
Afterwards, the region of interest of the IP fraction was removed using a proper 
sterile cutting device and the sample retrieved was stored in -80ºC. Samples were 
then sent to Dr. Thorsten Muller at the Functional Proteomics Department (Ruhr-
University Bochum) to be analyzed by liquid chromatography-electrospray tandem 
mass spectrometry. 
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IV. Results and Discussion 
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IV. 1. Confirm the existence of 
TCTEX1D4 in Prostate Cell Lines 
IV. 1. 1. A Protein Level Approach 
Preliminary results in our laboratory have suggested the presence of TCTEX1D4 in 
PCa cell lines, namely PC3 and LNCaP, using antibodies for TCTEX1D4 C- and N- 
terminus separately (Figure 8). In all cases, 100 μg of proteins from cell extracts 
were run in a 12% SDS-PAGE, immunoblotting with the respective primary 
antibodies was executed and detection was performed with Odissey 680 nm anti-
rabbit antibodies. For a positive control, a bacterial extract of TCTEX1D4-expressing 
vector was used.  
 
Figure 8 - TCTEX1D4 detection in prostate cancer cell l ines LNCaP and PC3 and in 
immortalized normal prostate epithelial cells RWPE-1. PC - Positive Control  
As depicted in Figure 8, a positive signal was detected in both cancer cell lines (PC3 
and LNCaP) using both antibodies. Nevertheless, the signal is weak, particularly 
using the N-terminal TCTEX1D4 antibody which may indicate low expression. The 
bands are present in the expected area, since they appear slightly above the 25 
kDa marker. Even though the predicted molecular weight for TCTEX1D4 is 23.4 
kDa, it may appear between 24.9 and 28.4 kDa due to possible post-translational 
events such as phosphorylation and glycosylation, as previously reported by 
Korrodi-Gregório et al [179].  
Also depicted in Figure 8 is the result of TCTEX1D4 detection in RWPE-1 cells using 
the antibody against the C-terminal of TCTEX1D4. Unlike in the cases of the PCa 
cell lines, no signal was detected. This suggests that TCTEX1D4 protein levels in 
normal epithelial cells are even lower, leading to the speculation that this protein 
may be upregulated in PCa cells. 
 
 
 
Anti-TCTEX1D4 N-terminal 
RWPE-1                 LNCaP                 PC3                    PC 
28 kDa 
28 kDa Anti-TCTEX1D4 C-terminal 
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However, in order to confirm the presence of TCTEX1D4 in all cell lines, IP assays 
were performed to purify the sample and increase the concentration of the protein, 
thus expecting to provide a better signal. 
Initially, IP with 5 μg of N-terminal TCTEX1D4 antibody was carried out. IP fractions 
were run through a 15% SDS-PAGE, immunoblotting was performed with anti-
TCTEX1D4 (N-terminal) antibody (1:1000) and detection was achieved with 
Odissey 680 nm anti-rabbit antibody (1:1000). Results (Figure 9A) indicate the 
presence of TCTEX1D4 in both cell lines tested.  
IP of TCTEX1D4 with 5μg of C-terminal TCTEX1D4 antibody also took place, 
followed by immunoblotting with the same antibody (1:1000). A TrueBlot secondary 
anti-rabbit antibody was used and detected using ECL. TrueBlot secondary 
antibodies mask the signal produced by immunoglobulins which are commonly 
detected in western blotting preceded by immunoprecipitation. Since TCTEX1D4 
molecular weight is similar to the molecular weight of immunoglobulin light chains 
(25 kDa), it was important to use such strategy to assure that signal was obtained 
from TCTEX1D4. Results are presented in Figure 9B. 
 
 
Figure 9 - Detection of TCTEX1D4 in LNCaP and PC3 cell l ines upon immunoprecipitation 
using N-terminal and C-terminal antibodies in A and B, respectively.  
Afterwards, a new detection of TCTEX1D4 protein was performed using IP with C-
terminal antibody in order to evaluate the presence of TCTEX1D4 in RWPE-1 cells, 
in which signal was not detected in a standard western blotting procedure (Figure 
8). 
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Figure 10 - Presence of TCTEX1D4 in RWPE-1, LNCaP and PC3 cell lines upon 
immunoprecipitation of TCTEX1D4 using C-terminal TCTEX1D4 antibody. IGLC – 
Immunoglobulin l ight chain 
The results (Figure 10) after IP seem to indicate the existence of TCTEX1D4 in 
RWPE-1, LNCaP and PC3 cells. However, since no signal was detected in RWPE-1 
cell line in a normal Western Blot (Figure 8), that may indicate that TCTEX1D4 
protein levels in RWPE-1 cells are not sufficient for detection with that technique 
and only after IP it is detectable. Moreover, since it is readily detected in PCa cell 
lines prior to IP, this may indicate overexpression of TCTEX1D4 at the protein level 
in malignant cells. 
The conjugation of the different results clearly demonstrates the existence of 
TCTEX1D4 at the protein level in all cell lines. Until now, TCTEX1D4 protein has 
never been described as present in prostate, either in normal or in pathological 
states. Nevertheless, TCTEX1D4 appears to be present at low levels and results 
seem to indicate that overexpression of TCTEX1D4 protein may occur in PCa cells. 
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IV. 1. 2. A mRNA level approach 
Firstly, in order to optimize the relative quantification of TCTEX1D4 and PPP1CC 
mRNA using qPCR, a series of preliminary experiments took place with the following 
objectives:   
a) Assess the quality of the available cDNA and decide the amount required to 
be used in the procedure, via the analysis of the results of the housekeeping 
genes;  
b) Determine the possibility of formation of primer dimers; 
c) Evaluate the quality of the primers, via the analysis of the obtained cp 
values and melting temperatures;  
d) Optimize the qPCR conditions for each primer, performing qPCR experiments 
at different annealing temperatures, namely 58º, 60º and 64ºC 
e) Evaluate the possibility of utilization of placenta cDNA as a positive control 
for TCTEX1D4. 
After this optimization step was finished, some conclusions were drawn that helped 
design the subsequent experiments:  
a) The quality of the cDNA was good and best results were achieved using 0.6 
μl of cDNA (circa 150 ng); 
b) Some primer pairs were excluded due to formation of primer dimers, low-
performance or presence of multiple melting temperatures, namely GAPDH, 
GAPDH-001, b-actin_hs, PAPTEIE, PAPTT57, PAPTGCH and TCTEX1D4-201. 
Regarding the remaining, GAPDH_hs, PPP1CC96, TCTEX1D4-001 and 
TCTEX1D4_hs2  were considered to be the optimal primer pairs to use; 
c) 45 annealing cycles at 60ºC conditions were chosen for qPCR;  
d) Placenta cDNA was shown to be a suitable positive control. 
TCTEX1D4 was detected in all situations and the ratio GAPDH/TCTEX1D4 seems to 
indicate a low expression of TCTEX1D4 even in the positive control (placenta), since 
the ratio GAPDH/TCTEX1D4 was 0.8. Since TCTEX1D4 expression is highly 
downregulated in the prostatic samples (vs. placenta), all data indicates a very low 
expression of TCTEX1D4 in the prostatic samples, coherent with the low expression 
detected at the protein level. Results are presented in Table 15 and Figures 11 and 
12. 
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Figure 11 – Expression ratios for all the samples tested taking Placenta as positive 
control 
The results indicate that TCTEX1D4 mRNA is present in all cell lines tested, as well 
as in the normal prostate tissue, although at very low levels. Such results are also a 
breakthrough since mammal EST analysis profiles for TCTEX1D4 available at 
UniGene do not contemplate TCTEX1D4 as being expressed at the mRNA level in 
prostate tissues. 
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IV. 1. 3. Assessing differences of TCTEX1D4 and PPP1CC 
expression 
The REST tool was used to statistically analyze the results of qPCR. Figure 12 
illustrates de expression ratios of TCTEX1D4 and PPP1CC between the cell samples 
analyzed vs. normal prostate sample. 
 
Figure 12 - Expression ratio of TCTEX1D4 and PPP1CC in LNCaP, DU 145 and PC3 cell, 
with prostate as control. Blue bar – TCTEX1D4 and Red bar – PPP1CC  
In Table 15 are listed the expression ratios for each case. Results over 1.5-fold or 
below 0.75-fold are presented in bold and represent situations of intense 
upregulation or downregulation, respectively. The results seem to indicate a 
progressive downregulation of PPP1CC parallel to PCa progression. Concerning to 
TCTEX1D4 results, it appears that in both PC3 and LNCaP cell lines its expression is 
downregulated, whilst in DU 145 it is intensively upregulated. Since results at the 
protein level point towards overexpression in PC3 and LNCaP cell lines vs. RWPE-1, 
it may indicate a strong regulation of TCTEX1D4 levels in the post-translational 
level or in its catalytic rate. Proteins involved in signal transduction are often tightly 
regulated and its expression levels are commonly largely altered upon stimulation.  
Table 15 – Expression ratios of TCTEX1D4 and PPP1CC between the tested samples and 
the normal prostate 
Target LNCaP DU 145 PC3 
TCTEX1D4 0,737 2,354 0,058 
PPP1CC 0,793 0,586 0,278 
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Nevertheless, it is important to highlight two aspects which may introduce some 
difficulties in understanding the results: 1) the protein levels of both TCTEX1D4 and 
PPP1CC in DU 145 were never assessed during this work and, thereof, it is not 
possible to evaluate if the mRNA levels are coherent with the protein levels in this 
cell line; 2) Expression ratios were calculated vs. cDNA extracted from normal 
prostate tissue and not from isolated epithelial cells. Therefore, it may not be the 
most suitable control. 
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IV. 2. Confirm the existence of 
TCTEX1D4-PPP1 complex and evaluate 
the possible existence of other 
TCTEX1D4 complexes 
The confirmation of existence of TCTEX1D4 in the cell lines created the need to 
evaluate TCTEX1D4 interactions in these cell lines. With only two articles published 
concerning this protein possible functions, the interactions already described are 
with PPP1 (in sperm) and with receptors of TGFβ signaling pathway, namely 
Endoglin (upon transfection in HEK293 cells). Thereof, it was of great interest to 
evaluate if such interactions are still present in prostate cell lines and, if possible, 
clarify such interactions and identify new ones. In order to do so, Co-IP and Mass 
Spectrometry techniques were applied. 
IV. 2. 1. A Co-IP-based approach 
TCTEX1D4-PPP1 
TCTEX1D4 has been described as a PPP1 Interacting Protein (PIP). This interaction 
was firstly identified in a testis yeast two-hybrid and later confirmed by yeast co-
transformation and co-immunoprecipitation in transfected cells. One of the 
hallmarks of interactions with PPP1 is the need for a physical binding between PPP1 
and the PIP. Therefore, one of the strategies to detect PIPs is via Co-
Immunoprecipitation assays. Henceforth, it was proposed to use co-
immunoprecipitation in the available cell lines in order to confirm the referred 
interaction. 
PPP1 is a ubiquitously expressed protein. Nevertheless, a confirmation of the 
existence of PPP1 in the samples has been carried out. Primarily, a Western Blot to 
detect both alpha and gamma isoforms of PPP1 was performed with the results 
being displayed in Figure 13. In this case, primary antibodies against PPP1CA and 
PPP1CC were used to detect their respective targets. 100 μg of protein sample of 
the cell extracts were run through a 12% SDS-PAGE. 
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Figure 13 - PPP1CA and PPP1CC detection on RWPE-1, LNCaP and PC3 cell l ines 
As depicted in Figure 13, both isoforms were detected in all cell lines.  
In order to confirm the possible interaction, TCTEX1D4 was precipitated using 5 μl 
of anti-C-terminal of TCTEX1D4 antibody, using as samples LNCaP and PC3 cells, in 
which TCTEX1D4 levels are proposed to be higher. Immunoblotting with the 
PPP1CA antibody was performed and detection took place using the Odissey 680 
nm anti-rabbit antibody. Results are presented in the Figure 14A.  
The absence of a band at 37 kDa (the molecular weight of PPP1) seems to indicate 
that no interaction was detected in PC3 cells. On the other hand, there appears to 
be a weak signal in the IP fraction of the LNCaP cells, which may indicate the 
presence of a complex between PPP1CA and TCTEX1D4 in that particular cell line.  
Nonetheless, IP of PPP1CA using 3 μg of antibody anti-PPP1CA was performed 
followed by immunoblotting with antibody against C-terminal of TCTEX1D4 (Figure 
14B). A double band at 25 kDa is visible, particularly perceptible in LNCaP cells, 
consistent with the idea of an interaction. Furthermore, the fact that this reversed 
approach to the complex granted much more clear results, may mean that the 
antibody for C-terminal of TCTEX1D4 is not particularly suitable for IP procedures. 
Naturally, the next step was to verify the presence of a PPP1CC-TCTEX1D4 
complex. In order to do so, IP of TCTEX1D4 was performed. Immunoblotting with 
anti-PPP1CC (1:5000) took then place and the results are presented in Figure 14C. 
The results may indicate the existence of PPP1CC in the IP fraction of LNCaP, 
despite the weakness of the signal obtained, which points towards the presence of 
interaction between PPP1CC and TCTEX1D4. Signal is absent in the IP fraction of 
PC3 cells. Once again, such results may be due to poor performance of the referred 
TCTEX1D4 C-terminal antibody in IP experiments.  
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Figure 14 - Results of the Co-IPs performed to evaluate the possibility of existence of a 
TCTEX1D4-PPP1 complex. 
 
TCTEX1D4-Endoglin 
TCTEX1D4 has been found to interact with several members of the TGFβ-signaling 
pathway. Of particular relevance, it was found to associate with Endoglin, 
Betaglycan, ActRIIA and TβRII, all of which are commonly downregulated in cases 
of PCa. Therefore, since these cell lines represent prostate cancer cells, it was 
interesting to assess the possibility of an interaction between TCTEX1D4 and 
Endoglin. Although it is described as an endothelial co-receptor for TGFβ, intense 
alterations in Endoglin function have been described in PCa and therefore the 
possibility of existence of such interaction was evaluated. In order to do so, an IP of 
TCTEX1D4 using anti-TTCTEX1D4 C-terminal antibody was performed following the 
procedure already described. Afterwards, immunoblotting using antibody against 
Endoglin was performed. The results are depicted in Figure 15A. 
Even though some signal appears in the 50 kDa area, which may correspond to the 
S-Endoglin form, it is way too weak. Therefore, the results do not clearly 
demonstrate the previously described interaction between Endoglin and TCTEX1D4. 
Nevertheless, poor performance of this antibody in IP may account for the absence 
of results. Moreover, the interaction may be indirect. 
 
PPP1-Endoglin 
Since Endoglin has been shown to bind to TCTEX1D4 and TCTEX1D4 is a PIP, it was 
proposed that it is the complex PPP1-TCTEX1D4 that binds to Endoglin. Therefore, 
it was decided to try to find evidences concerning the possibility of existence of a 
binding between PPP1 and Endoglin, thus forming a putative trimeric complex. In 
order to do so, IPs of PPP1CA and PPP1CC were prepared using 3 μg of the 
respective antibodies using as samples 2 Petri dishes of 100 mm of PC3 and LNCaP 
cells. Immunoblotting was then carried out using antibody against Endoglin which 
25 kDa 
(IGLC) 
28 kDa  
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was detected using 800 nm anti-mouse Odissey antibo dy. Results are presented in 
Figure 13B.  
Once again, signal appears in the 55 kDa area, which may correspond to the S-
Endoglin form. In this case, however, the signal is much stronger that in the 
previous one, thus pointing towards an interaction between both PPP1 isoforms and 
Endoglin in the cell lines tested. 
 
Figure 15 – Co-IP assays performed to evaluate the possibil ity of  existence of Endoglin-
TCTEX1D4 and Endoglin-PPP1CC complexes in LNCaP and PC3 cells  
The results so far seem to strongly indicate an interaction 
between PPP1 and TCTEX1D4 and between PPP1 and 
Endoglin. The results do not clearly indicate a direct 
interaction between TCTEX1D4 and Endoglin, thus we 
raised the possibility of the existence of a trimeric complex 
of TCTEX1D4-PPP1-Endoglin, as depicted in Figure 16. 
  
 
Figure 16 - Proposed trimeric complex 
 of TCTEX1D4-PPP1-Endoglin 
 
  
55 kDa 55 kDa 
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IV. 2. 2. A Mass Spectrometry-based approach 
In order to identify the interaction between TCTEX1D4 and PPP1 a Mass 
Spectrometry analysis was performed. TCTEX1D4 IP using the C-terminal antibody 
was carried out. Extracts from PC3, LNCaP and RWPE-1 cells were used and the 
area of the IP fraction that was retrieved was between 25 and 40 kDa (Figure 17) 
to include not only the TCTEX1D4 but also the PPP1 region. Other possible 
interactors may also be identified using this technique 
 
Figure 17 - Regions of the IP fractions of TCTEX1D4 sent to MS analysis  
Regarding this subject, we are still currently awaiting the arrival of the results, 
which may not only confirm the proposed interaction between PPP1 and TCTEX1D4 
but also identify other unpredicted complexes. 
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IV. 3. Localize TCTEX1D4 at the cellular 
and histological level 
TCTEX1D4 localization in human sperm cells and upon transfection was previously 
described. Nonetheless, no studies regarding native TCTEX1D4 localization in 
human prostate cells were already published. Therefore it was of great interest to 
localize TCTEX1D4 in the normal and malignant prostate cells. In all cases, antibody 
against the C-terminal of TCTEX1D4 was used. 
IV. 3. 1. TCTEX1D4 in normal and malignant prostate cells 
Normal Cells - RWPE-1 
RWPE-1 cells are commonly used to represent normal prostate epithelial cells, 
immortalized upon transfection of HPV-18. In these cells, TCTEX1D4 is present 
throughout the cytoplasm and nucleus, in a dispersed fine punctuate pattern 
(Figure 18). 
 
Figure 18 - Localization of TCTEX1D4 in RWPE-1 cells 
 
Malignant cells – LNCaP and PC3 
The androgen-dependent LNCaP cells represent moderately aggressive PCa cells. In 
this cell line, TCTEX1D4 localization (Figure 19) is delimited within the cytoplasm to 
a polarized and very restricted area in which large dots are visible producing a very 
intense signal. This may localize TCTEX1D4 to aggregates, vesicles or some 
organelle. The presence of signal in the nucleus is rather scarce (19B). 
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Figure 19 - Localization of TCTEX1D4 in LNCaP cells  
PC3  
 
Figure 20 - Localization of TCTEX1D4 in PC3 cells  
The androgen-independent PC3 cells represent highly aggressive PCa cells. In these 
cells, TCTEX1D4 was localized in the cytoplasm and almost completely absent from 
the nucleus. As depicted in Figure 20, the localization of TCTEX1D4 in this cell line 
appears to be less restricted than in LNCaP cells, but still much more localized if 
compared with normal cells. The pattern produced was of a number of medium-
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sized dots which may also be restricted or correspond to some sort of vesicles, 
organelles or aggregates. In some cells in particular (20B), TCTEX1D4 was localized 
in a very restricted area in the vicinity of the nucleus, in a polarized manner, more 
similar to the pattern observed in LNCaP cells. As observed in LNCaP cells, the 
signal produced appeared to be more intense than the one present in RWPE-1 cells. 
Korrodi-Gregório et al. studies [179] have localized TCTEX1D4 along the flagellum, 
in the region of the mitochondria and in the acrosome of sperm cells. Upon 
transfection, it was localized across the cytoplasm, in the microtubules and the 
MTOC of GC1-spg and COS-7 cells. Previously, Meng et al. [178] localized 
TCTEX1D4 in vesicles, microtubules and nucleus, upon transfection in HeLa cells. 
Regarding TCTEX1D4 localization in RWPE-1, LNCaP and PC3 cells, the results seem 
to indicate a rather interesting difference in the pattern of its subcellular localization 
between normal and malignant cells (Table 16). Taking into account the limited 
published information regarding such matter, it may be suitable to speculate if in 
RWPE-1 cells the TCTEX1D4 observed throughout the cytoplasm is associated with 
microtubules and if the more restrictedly localized signals observed in PCa cells 
correspond to vesicles.  
Other aspect that may be of interest is the fact that the TCTEX1D4 pattern in PC3 
cells appears to be somewhat between the ones observed for LNCaP and RWPE-1 
cells, despite the fact that PC3 represents a more aggressive PCa cell line than 
LNCaP. One factor that may contribute to elucidate this is that LNCaP cells, unlike 
PC3 cells, are often reported to be TGFβ-insensitive and absence of TGFβRs in 
LNCaP cells is commonly found. Therefore, since in LNCaP cells profound alterations 
of TGFβ signaling are present, and being TCTEX1D4 a proposed element of this 
signaling pathway, a more extended disruption of TCTEX1D4 localization or function 
in this cell line may be expected. 
Table 16 - Differences in localization of TCTEX1D4 between the cell lines tested. "+" - 
abundant, "-" - scarce and "0" - absent 
Signal of 
TCTEX1D4 
RWPE-1 LNCaP PC3 
Cytoplasm 
Throughout the 
cytoplasm 
Very restricted and 
polarized 
Restricted 
Nucleus + - 0 
Pattern Fine punctuate Large dots Medium-sized dots 
Intensity Weaker Strongest Stronger 
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IV. 3. 2. TCTEX1D4 in normal prostate and in prostate tumors 
In order to identify TCTEX1D4 in prostate tumor samples, a first round of 
immunohistochemistry was performed. As samples, tissue section from tumors 
generated in nude mice upon implantation of LNCaP, PC3, LuCaP 23.1 and DU 145 
prostate tumor cells were used. These sections were paraformaldehyde-fixed and 
paraffin-embedded and were kindly provided by Dr. Tobias Lunge. Both antibodies 
against C- and N-Terminus of TCTEX1D4 were used and a range of dilutions (from 
1:50 to 1:1000) was tested. Unfortunately, no positive results were found in any 
case (data not shown). In order to address this issue, optimization of the 
methodology was necessary and a key aspect noticed was the absence of a proper 
positive control. Since TCTEX1D4 localization in human tissues was never described 
before, a search for a positive control was undertaken in order to assess if the 
absence of results was due to lack of protein or due to some methodological 
problem. 
TCTEX1D4 in Placenta – a positive control 
A NCBI EST database analysis for TCTEX1D4 mRNA in mammals has found hits in 
female reproductive tract (ovary, oviduct, placenta, uterus and embryonic tissues), 
head-related tissues (such as brain and tongue) and lung. Thereof, the following 
tissues were initially tested as possible positive controls: 
a) Normal lung 
b) Tumors derived from the implantation of OH3 and H69 cancer cells in nude 
mice (small cell lung carcinoma cell lines) 
c) Placenta 
All the samples used so far had been fixed with paraformaldehyde and paraffin-
embedded. Since once again the results were negative for all the tested samples, it 
was raised the possibility that was the treatment of the samples that constituted a 
problem that needed to be circumvented. It was also suggested that the use of 
cryopreserved samples may be more suitable, due to the fact that epitopes may be 
more accessible to the primary antibody. 
Thusly, fresh placenta samples were collected and cryopreserved with either a 
previous brief fixation with paraformaldehyde followed by a sucrose gradient or 
flash frozen without any previous treatment. Immunhistochemistry experiments 
were performed, using antibody against the C-terminal of TCTEX1D4 as primary 
antibody (1:150 and 1:300 dilutions) and the secondary antibody used was anti-
rabbit Cy3. Samples cryopreserved without fixation were defined as negative, but a 
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distinct positive signal was found in the fixed and then cryopreserved samples. A 
strong signal was found to be present in cells of the villi of the placenta (which may 
be compatible of DLC function of TCTEX1D4), particularly in the ones of central 
localization (Figure 21). The signal was of a non-nuclear fine punctuate pattern. 
From this point on, placenta has been regarded as a positive control for TCTEX1D4 
at the tissue level. 
 
Figure 21 - TCTEX1D4 localization in the placenta tissue 
TCTEX1D4 in Normal Prostate 
Prostate samples were subjected to the same treatment that has revealed to be 
suitable for the placenta and the immunohistochemistry was performed under the 
same conditions. The results are presented in Figure 22. Positive signals were found 
and, like as observed in placenta, signals appeared as a non-nuclear fine punctuate 
pattern. However, it was not as intense or as common as observed in the placenta. 
Nevertheless, signal appears to be specific. Interestingly, only few cells per field 
demonstrate a positive signal. The low rate of positive cells stained may indicate 
that only a subset of prostate cells express TCTEX1D4. Stained cells did not appear 
to be glandular epithelial cells and the frequency of circa 5-10% positive cells may 
indicate that these cells correspond to a particular subset of cells, such as 
neuroendocrine or stem cells of the prostate. 
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Figure 21 - TCTEX1D4 localization in the Prostate. In the merge image, arrows  point out 
some cells stained positively. The box corresponds to the region of interest shown in the 
merge image. 
TCTEX1D4 in Prostate Tumors  
Cryopreserved tumor samples retrieved from xenografts generated upon 
implantation of LNCaP and PC3 cells in nude mice were available. IHC was 
performed in these samples under the established optimized conditions and the 
results are presented in Figure 22. 
Unlike the observed in the normal prostate, in tumor samples TCTEX1D4 appears to 
be ubiquitous and distributed all throughout the tissue. Moreover, the signal 
produced is more intense and the pattern produced is also distinct: in these 
samples the signal appears as medium-sized dots which may correspond to vesicles 
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or aggregates, as previously proposed in the subcellular localization of TCTEX1D4 in 
PCa cell lines. 
 
Figure 22 -TCTEX1D4 localization in LNCaP (A.) and PC3 (B.) derived tumors  
Therefore, much like what it was observed for the prostate cells, encouraging 
differences in the tissue localization of TCTEX1D4 between the normal prostate and 
the tumor samples have been observed (Table 17). Furthermore, this work has 
established placenta as a TCTEX1D4 positive control for IHC. 
Table 17 – Differences in the signal of TCTEX1D4 in the tissues analyzed  
Signal of 
TCTEX1D4 
Normal Placenta Normal Prostate Tumor samples 
Distribution 
Several cells of 
central localization 
Restricted to a 
small subset of 
cells 
Throughout all the 
sample 
Pattern Fine punctuate Fine punctuate 
Medium and large-
sized dots 
Intensity Stronger Weak Stronges 
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IV. 4. Co-localize TCTEX1D4 and other 
proteins of interest 
IV. 4. 1.  Cellular level 
In order to fulfill the objective of elucidating the role of TCTEX1D4 in the TGFβ 
signaling pathway in PCa, it is of crucial importance to figure out its place within the 
pathway. As DLC, it may play a role a role in the translocation of the signal towards 
the nucleus. Thus it may interact with receptors, co-receptors or with Smads. As its 
interaction and co-localization with Endoglin, TGFβRII and Betaglycan has already 
been studied, it was proposed to study its possible interaction with Smads. Due to 
the fact that it has been already demonstrated that it is possible that specific Smad 
pathways require specific DLCs, it was evaluated the co-localization of TCTEX1D4 
with Smad 1, Smad 2 and Smad 3. Moreover, since the hypothesis of existence of a 
trimeric complex of TCTEX1D4-PPP1-Endoglin has been raised, co-localization 
studies with these proteins were also performed. All these studies were performed 
in RWPE-1, LNCaP and PC3 cell lines. 
 
TCTEX1D4-ENDOGLIN 
As predicted in the Co-IP procedures, the possible direct interaction between 
Tctex1d4 and Endoglin in PCa cells appears to be almost absent and very limited, 
since only a small number of co-localization spots were found in LNCaP and PC3 
cells (Figures 24 and 25). On the other hand, in RWPE-1 cells such interaction may 
occur at an increased extent, since a much larger number of co-localization spots 
are observed, clearly depicted in Figure 23. This may indicate that there is a 
progressive decrease of TCTEX1D4-Endoglin interaction during malignant 
transformation. Notice that no Co-IP studies were performed in this cell line and, 
thereof, no other indication of such interaction is currently available. 
Regarding the localization of that interaction, co-localization was found in 
cytoplasm. Notice that co-localization of Endoglin-TCTEX1D4 was previously 
reported by Meng et al. has been mostly localized in the cell membrane and cell 
protrusions and seldom in vesicles [178].  
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RWPE-1 
 
Figure 23 - Co-localization studies of TCTEX1D4 (red) and Endoglin (green) in RWPE -1 
cells 
LNCaP 
 
Figure 24 - Co-localization studies of TCTEX1D4 (red) and Endoglin (green) in LNCaP 
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PC3 
 
Figure 25 - Co-localization studies of TCTEX1D4 (red) and Endoglin (green) in PC3 cells 
 
PPP1CC-ENDOGLIN 
Co-localization between PPP1 and Endoglin has been observed in all cell lines, as 
predicted by the results of the Co-IP performed in PC3 and LNCaP cells lines which 
pointed towards an interaction between the two proteins (Figures 26 and 27). 
Regarding the localization of the co-localization it appears to be either in the 
cytoplasm (RWPE-1 and PC3, Figures 26 and 27 - right) or in the nucleus (LNCaP, 
Figure 27 - left). Nevertheless, it must be highlighted that the antibody against 
Endoglin performed poorly in all ICC experiments, producing weak signal and 
excessive background. 
Once again, it appears to occur a decrease of the co-localization from normal to 
malignant cells. All the results so far seem to indicate a progressive disruption of 
the putative trimer TCTEX1D4-PPP1-Endoglin during acquisition of malignity, as co-
localization is decreased in prostate cancer cells. 
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RWPE-1 
 
Figure 26 - Co-localization studies of PPP1CC (red) and Endoglin (green) in RWPE-1 cells 
LNCaP and PC3     
 
Figure 27 - Co-localization studies of PPP1CC (red) and Endoglin (green) in LNCaP (left) 
and PC3 (right) cells  
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Another interesting result is the fact that in LNCaP cells PPP1CC localization appears 
to be restricted to the nucleus, unlike in the other cell lines in which PPP1CC protein 
is also localized throughout the cytoplasm (Figure 28). 
 
Figure 28 - Localization of PPP1CC in RWPE-1, LNCaP and PC3 cell lines 
 
TCTEX1D4-SMADs 
Co-localization studies of TCTEX1D4 with Smad 1, Smad 2 and Smad 3 were 
performed for RWPE-1, LNCaP and PC3. No signal for Smad 1 or Smad 2 was visible 
in any of the experiments (data not shown). Regarding co-localization of Smad 3 
with TCTEX1D4 the results are presented in Figures 29, 30 and 31. 
As depicted in Figure 29, co-localization of TCTEX1D4 and Smad 3 was observed in 
RWPE-1 cells but no co-localization was noticeable in both LNCaP and PC3 cells 
(Figures 30 and 31). This may indicate that TCTEX1D4 interacts with Smad 3 in 
normal cells and that this interaction is disrupted in malignant cells. In normal cells, 
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TCTEX1D4 may act as DLC in the Smad 3-mediated pathway intervening in the 
nuclear translocation of Smad 3, whilst in malignant cells TCTEX1D4 may be re-
allocated to other non-canonical pathways. This is in accordance with the reported 
decrease in Smad 2/3 signaling observed in PCa. 
RWPE-1 
 
Figure 29 - Co-localization of TCTEX1D4 and Smad 3 in RWPE-1 cells 
LNCaP 
 
Figure 30 - Co-localization of TCTEX1D4 and Smad 3 in LNCaP cells  
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PC3  
 
Figure 31 - Co-localization of TCTEX1D4 and Smad 3 in PC3 cells  
 
IV. 4. 2. Prostate tissue 
Co-localization studies of TCTEX1D4 and PPP1CC with Endoglin were performed. No 
signal for PPP1CC was observed and the signal of Endoglin in normal prostate and 
normal placenta tissue was restricted, as expected, to endothelial cells, producing a 
distinct signal in the apical membrane, depicted in Figures 32 and 33. Thus, no co-
localization was observed in the normal prostate or in the normal placenta. 
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Figure 328 - Localization of TCTEX1D4 (green) in normal prostate  
 
 
Figure 33 - Localization of TCTEX1D4 (green) in normal placenta  
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V. Conclusions and  
Future Work 
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V. 1. Conclusions 
This work has contributed to increase our knowledge of TCTEX1D4 protein in 
human prostatic cells. Since this is a practically unknown protein, with only two 
published articles addressing its possible functions, this work faced many 
complications related to the fact that most techniques were not previously 
optimized for this protein. Moreover, the absence of information related to its 
functions, expression levels and localization made it more difficult to characterize it 
and give the results biological significance. Thereof, the results presented must be 
seen as preliminary and the proposed models, alterations and functions need to be 
further confirmed by proof-of-concept methodologies. Nevertheless, the main 
conclusions retrieved from this work are: 
i. It was demonstrated, for the first time, the existence of TCTEX1D4 in normal 
prostate and in prostate cancer cells, both at the mRNA and at the protein 
levels 
ii. TCTEX1D4 subcellular localization differs from normal prostate cells 
(throughout the cytoplasm and nucleus) to prostate malignant cells 
(polarized to a restricted region of the cytoplasm) 
iii. TCTEX1D4 in normal prostate tissues was localized to a small subset of cell 
in which a fine punctuate weak signal is observed. On the contrary, in 
prostate tumors a strong TCTEX1D4 signal was detected in large dots all 
throughout the samples 
iv. Placenta was defined as a suitable control for TCTEX1D4 at the mRNA level 
and for immunohistochemistry assays, in which a distinctive specific signal 
was for the first time described 
v. Results from Co-Immunoprecipitation assays indicate the presence of a 
TCTEX1D4-PPP1 interaction.  
vi. Results from Co-Immunoprecipitation assays and Immunocytochemistry co-
localization studies point towards the presence of a PPP1-Endoglin 
interaction. Such interaction may be more common in normal cells 
vii. Co-Immunoprecipitation assays did not indicate the presence of a 
TCTEX1D4-Endoglin interaction in prostate cancer cells. Furthermore, 
immunocytochemistry co-localization studies indicate that co-localization of 
Endoglin-TCTEX1D4 may be found in all cell lines but appears to occur at 
much higher extent in normal prostate cells (RWPE-1) 
viii. TCTEX1D4-Smad 3 co-localization was found solely in normal cells (RWPE-1) 
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ix. At the tissue level, no co-localization was found between Endoglin and 
TCTEX1D4  
x. A progressive decrease in mRNA levels of PPP1CC is found to occur parallel 
to progression of PCa cells malignity 
xi. PPP1CC localization in LNCaP cells appears to be essentially nuclear, whilst 
PPP1CC is spread throughout the nucleus and cytoplasm in RWPE-1 and PC3 
cells 
In summary, this work raised several hypotheses: 
 TCTEX1D4 subcellular localization is proposed to be altered in case of 
cancer. It is speculated if during the malignant transformation it is 
reallocated into a specific organelle, associated with microtubules or if it 
aggregates 
 In normal prostate tissue TCTEX1D4 is restricted to a small number of 
cells, while in cancer it is detected throughout the sample. Therefore, it 
is speculated if there is a overexpression of TCTEX1D4 in prostate 
tumors, thus resulting in the presence of such differences in terms of 
staining patterns 
 Results led to the proposed model of a trimeric complex of TCTEX1D4-
PPP1-Endoglin. Furthermore, it is proposed that such complex may be 
disrupted during cancer progression, since co-localization of TCTEX1D4-
Endoglin and PPP1-Endoglin are mostly observed in RWPE-1 
 TCTEX1D4-Smad 3 complex may be disrupted during cancer progression. 
TCTEX1D4 may act in the nuclear translocation of Smad 3 in normal cells 
and the referred alteration in malignant cells may contribute to decrease 
Smad 3 signaling, a feature commonly observed in PCa 
Other results from our laboratory indicate that TCTEX1D4 play a role in proliferation 
of prostate cells (both normal and malignant) and such effect may be modulated by 
phosphorylation events. Such results, in conjunction with the ones hereby 
presented, raise the possibility that TCTEX1D4 may play an active role during 
malignant transformation. Moreover, it appears that TCTEX1D4, via the interaction 
with Endoglin and Smad 3, may contribute to the disruption of TGFβ signaling, 
commonly observed in PCa. 
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V. 2. Future Work 
The next steps necessary to test the hypotheses raised and further understand the 
role of TCTEX1D4 in TGFβ signaling and PCa are already defined.  
Firstly, it is necessary to validate all the interactions proposed, using reversed Co-
IP in the situations in which such was not yet performed.  
Furthermore, TCTEX1D4 protein quantification is required, since results from qPCR 
were not easily understandable.  
In order to describe precisely the subcellular localization of TCTEX1D4, the 
utilization of subcellular markers is necessary. Such strategy is also necessary to 
identify in which subset of cells TCTEX1D4 is detected in prostate tissue.  
Moreover, to clarify the role of TCTEX1D4 in TGFβ pathway, luciferase assays will 
be performed to address by which Smad pathways the signal is translocated, upon 
transfection of TCTEX1D4 and stimulation with TGFβ, BMPs and Activins. 
Regarding to its role in PCa, overexpression (by transfection) and knock-down (by 
shRNA) will be performed and the effects on cellular proliferation and migration will 
be evaluated. 
Following these strategies, it is expected to achieve a better understanding of 
TCTEX1D4 role in TGFβ signaling pathway and in PCa development. 
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Appendix I - Solutions 
Lower Gel Buffer 
   
 
To 900 ml of deionized H2O add: 
 
Tris 181.65 g 
  
 
SDS 4 g 
   
 
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1L with 
deionized H2O. 
     Upper Gel Buffer 
   
 
To 900 ml of deionized H2O add: 
 
Tris 75.69 g 
  
 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1L with 
deionized H2O. 
     30% Acrylamide/0,8% Bisacrylamide 
 
 
To 70 ml of deionized H2O add: 
 
Acrylamide 29.2 g 
  
 
Bisacrylamide 0.8 g 
  
 
Mix until the solutes have dissolved. Adjust the volume to 100 mL with deionized water. Filter 
through a 0.2 μm filter and store at 4 °C. 
     10% Ammonium persulfate 
  
 
In 10 ml of deionized H2O dissolve 1 g of APS. 
     10% SDS (Sodium dodecilsulfate) 
 
 
In 10 ml of deionized H2O dissolve 1 g of SDS. 
     4x LB (Loading buffer) 
  
 
1 M Tris solution (pH 6.8) 2.5 ml (250 mM) 
 
SDS 0.8 g (0.8%) 
  
 
Glycerol 4 ml (40%) 
  
 
β-Mercaptoethanol 2 ml (2%) 
 
 
Bromophenol blue 1 mg (0.01 %) 
 
Adjust the volume to 10 ml with deionized H2O. Store in darkness at RT. 
     1 M Tris (pH 6.8) solution 
  
 
To 150 ml of deionized H2O add: 
 
Tris base 30.3 g 
  
 
Adjust the pH to 6.8 and adjust the final volume to 250 ml. 
     10x Running Buffer 
   
 
Tris 30.3 g (250 mM) 
  
 
Glycine 144.2 g (2.5 M) 
 
 
SDS 10 g (1%) 
  
 
Dissolve in deionized H2O, adjust the pH to 8.3 and adjust the volume to 1 L. 
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     10x Transfer Buffer 
   
 
Tris 3.03 g (25 mM) 
  
 
Glycine 14.41 g (192 mM) 
 
 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 ml with 
deionized H2O. Just prior to use add 200 ml of methanol (20%). 
     10x TBS 
    
 
Tris 12.11 g (10 mM) 
  
 
NaCl 87.66 g (150 mM) 
 
 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionized H2O. 
     10x TBS-T 
    
 
Add 5 ml (0.05%) of Tween 20 to 1 L of 10x TBS 
     1x TBS-TT 
    
 
Add 2 ml (0.2%) of Triton X-100 to 1 L of 1x TBS-T 
     1x PBS-Triton X-100 
   
 
Add 2 ml (0.2%) of Triton X-100 to 1 L of 1x PBS 
     10% FBS-PBS 
   
 
Add 50 ml of FBS to 450 ml of 1x PBS 
     4% paraformaldehyde-PBS 
  
 
Add 4 grams of paraformaldehyde to 80 ml of 1x PBS  
 
Adjust pH to 7.4 and the volume to 100 ml 
     3% milk-TBS-T solution 
  
 
Add 30 g of powdered milk to 1 L of 1x TBS-T 
     5% milk-TBS-T solution 
  
 
Add 50 g of non-fat powdered milk to 1 L of 1x TBS-T 
     3% Bovine Serum Albumin (BSA) solution 
 
Add 30 g of BSA to 1 L of 1x TBST-T 
     1X RIPA lysis buffer with protease inhibitors 
 
Mix the following (μl) in 8101 μl of deionized water: 
 
 
10x RIPA lysis buffer 1000 
  
 
PMSF (100X) 100,0 
  
 
Benzamidine 500,0 
  
 
Pepstatin A 100,0 
  
 
Leupeptin 10,0 
  
 
Aprotitin 88,8 
  
 
EGTA 100,0 
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Protease inhibitiors 
preparation 
    
 
Inhibitor Weight (mg) 
Volume of 
solvent (ml) 
Solvent and storage 
 
PMSF (100X) 17,42 1 
Isopropanol, Ethanol or Methanol 
and store at -20°C 
 
Benzamidine 24,03 5,13 H20 and store at 4°C 
 
Pepstatin A 0,34 5 Methanol or DMSO and store at 4°C 
 
Leupeptin 0,93 1 
H20, ethanol or DMF and store at -
20°C 
 
Aprotitin 1,10 1 
H20 with 0,9% NaCl and 0,9% 
Benzyl-Alcohol and store at 4°C 
 
EGTA 38,04 100 
H20, adjust the pH to 8.0 and store 
at RT 
     Fixing Solution 
    
 
Add 500 ml of methanol and 100 ml of 
glacial acetic acid to 400 ml of deionized 
water 
   
     Staining 
solution 
    
 
Add 1 ml of Coomassie Brilliant Blue R-250 
to 1 L of Fixing Solution  
   
     Distaining 
solution 
    
 
add 400 ml of methanol and 100 ml of 
glacial acetic acid to 500 ml of deionized 
water 
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Appendix II – Primers 
Target Gene Name Sequences 
Predicted 
Annealing (ºC) 
GAPDH 
GAPDH 
f: 5’-aacgggaagcttgtcatcaatggaaa-3’ 
60 
r: 5’-aacgggaagcttgtcatcaatggaaa-3’ 
GAPDH-001 
f: 5'-ccccggtttctataaattgagc-3' 
60 
r: 5'-caccttccccatggtgtct-3' 
GAPDH_hs 
f: 5'-gacagtcagccgcatcttct-3' 
61 
r: 5'-gcgcccaatacgaccaaatc-3'   
beta-actin b-actin_hs 
f: 5'-ccacacaggggaggtgatag-3' 
60 
r: 5'-agaccaaaagccttcatacatctca-3'   
HPRT1 
HPRT 
f: 5’-gctataaattctttgctgacctgctg-3’ 
62 
r: 5’-aattacttttatgtcccctgttgactgg-3’ 
HPRT-001 
f: 5'-gaccagtcaacaggggacat-3' 
59 
r: 5'-gtgtcaattatatcttccacaatcaag-3' 
TCTEX1D4 
TCTEX1D4-001 
f: 5'-gtgagggggagtccaattct-3' 
59.5 
r: 5'-cagacacttatttattgggatgtga-3' 
TCTEX1D4-201 
f: 5'-gcctgggactatctgatcca-3' 
59.5 
r: 5'-ccggagtctttggcattc-3' 
PAPTEIE 
f: 5´- ccctgctcatgtgtctaacagcc-3’ 
58 
r: 5´- tttggcattctcctcctcctggc-3’ 
PAPTT57 
f: 5´- acagcctttaaccttctcagcacc-3’ 
57.5 
r: 5´- gcccggagtctttggcattctc-3’ 
PAPTGCH 
f 5´- aggagctcagtcggcaaggac-3’ 
59 
r: 5´- tggccatggacctgctgtgttttag-3’ 
TCTEX1D4_hs 
f: 5'-atcagaggccaaaggcagaag-3'   
60 
r: 5'-ccttcaaccccacagatcct-3' 
TCTEX1D4_hs2 
f: 5'-gtaggggagatctttgtgcca-3' 
60 
r: 5'-cccgacttctctggaaggag-3'   
PPP1CC 
PPP1CC96 
f: 5’- aacggctgctggaagtga – 3’ 
59.5 
r: 5'- agatttcacgagactttaagcaca- 3’ 
PPP1CC64 
f: 5’ – caacatcgacagcattatcca – 3’ 
59.5 
r: 5’ – gacattcttaccaggcttggac – 3’ 
 
